



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | | | | | | | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|----------------------------------------------------------------------------------------------------------------------------|----|------------|------------------------|----|------------|------------------------|----|------------|-----------------------------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (51) International Patent Classification ⁶ : A61K 7/50 | A1 | (11) International Publication Number: WO 98/55094 (43) International Publication Date: 10 December 1998 (10.12.98) | | | | | | | | | | | |
| <p>(21) International Application Number: PCT/US98/10973</p> <p>(22) International Filing Date: 29 May 1998 (29.05.98)</p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>08/869,116</td> <td>4 June 1997 (04.06.97)</td> <td>US</td> </tr> <tr> <td>08/868,688</td> <td>4 June 1997 (04.06.97)</td> <td>US</td> </tr> <tr> <td>08/868,687</td> <td>4 June 1997 (04.06.97)</td> <td>US</td> </tr> <tr> <td>08/969,057</td> <td>12 November 1997 (12.11.97)</td> <td>US</td> </tr> </table> <p>(71) Applicant: THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US).</p> <p>(72) Inventors: BEERSE, Peter, William; 8874 Pollard Place, Maineville, OH 45039 (US). MARGAN, Jeffrey, Michael; 8575 Highmont Drive, Springboro, OH 45066 (US). BAIER, Kathleen, Grieshop; 3660 Hanley Road, Cincinnati, OH 45247 (US). CEN, Wei; 8936 Cypresspoint Lane, Cincinnati, OH 45249 (US). BAKKEN, Theresa, Anne; 11956 Britesilks Lane, Cincinnati, OH 45249 (US). CLAPP, Mannie, Lee; 5042 Lexington Court, Mason, OH 45040 (US). WARREN, Raphael; 6715 West Farm Acres Drive, Amberly Village, OH 45237 (US).</p> | 08/869,116 | 4 June 1997 (04.06.97) | US | 08/868,688 | 4 June 1997 (04.06.97) | US | 08/868,687 | 4 June 1997 (04.06.97) | US | 08/969,057 | 12 November 1997 (12.11.97) | US | <p>(74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p> |
| 08/869,116 | 4 June 1997 (04.06.97) | US | | | | | | | | | | | |
| 08/868,688 | 4 June 1997 (04.06.97) | US | | | | | | | | | | | |
| 08/868,687 | 4 June 1997 (04.06.97) | US | | | | | | | | | | | |
| 08/969,057 | 12 November 1997 (12.11.97) | US | | | | | | | | | | | |
| <p>(54) Title: MILD, ANTIMICROBIAL WIPES</p> <p>(57) Abstract</p> <p>The present invention relates to an antimicrobial wipe comprising a porous or absorbent sheet impregnated with an antimicrobial cleansing composition, wherein the antimicrobial cleansing composition comprises from 1.001 % to 5.0 % by weight of the antimicrobial cleansing composition, of an antimicrobial active; from 0.05 % to 10 % by weight of the antimicrobial cleansing composition, of an anionic surfactant; from 0.1 % to 10 %, by weight of the antimicrobial cleansing composition, of a proton donating agent; and from 3 % to 99.85 %, by weight of the antimicrobial cleansing composition, water; wherein the composition is adjusted to a pH of from 3.0 to 6.0; wherein the antimicrobial cleansing composition has a Gram Positive Residual Effectiveness Index of greater than 0.5; and wherein the antimicrobial cleansing composition has a Mildness Index of less than 0.3. The present invention also relates to an antimicrobial wipe impregnated with an antimicrobial cleansing composition which has a Gram Positive Residual Effectiveness Index of greater than 0.5. It also relates to an antimicrobial wipe impregnated with an antimicrobial cleansing composition which has a One-wash Immediate Germ Reduction Index of greater than 1.3. The invention also encompasses methods for cleansing skin and providing residual effectiveness versus Gram positive bacteria using these products.</p> | | | | | | | | | | | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|------------------------------------------|----|----------------------------------------------|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

MILD, ANTIMICROBIAL WIPES

TECHNICAL FIELD

The present invention relates to cleansing wipes comprising absorbent sheets impregnated with antimicrobial cleansing compositions. Specifically, the cleansing wipe personal cleansing compositions of the invention provide previously unseen residual effectiveness against transient Gram negative bacteria, provide improved residual effectiveness against transient Gram positive bacteria, or provide previously unseen levels of immediate germ reduction during cleansing.

BACKGROUND OF THE INVENTION

Human health is impacted by many microbial entities. Inoculation by viruses and bacteria cause a wide variety of sicknesses and ailments. Media attention to cases of food poisoning, strep infections, and the like is increasing public awareness of microbial issues.

It is well known that the washing of hard surfaces, food (e.g. fruit or vegetables) and skin, especially the hands, with antimicrobial or non-medicated soap, can remove many viruses and bacteria from the washed surfaces. Removal of the viruses and bacteria is due to the surfactancy of the soap and the mechanical action of the wash procedure. Therefore, it is known and recommended that people wash frequently to reduce the spread of viruses and bacteria.

Bacteria found on the skin can be divided into two groups: resident and transient bacteria. Resident bacteria are Gram positive bacteria which are established as permanent microcolonies on the surface and outermost layers of the skin and play an important, helpful role in preventing the colonization of other, more harmful bacteria and fungi.

Transient bacteria are bacteria which are not part of the normal resident flora of the skin, but can be deposited when airborne contaminated material lands on the skin or when contaminated material is brought into physical contact with it. Transient bacteria are typically divided into two subclasses: Gram positive and Gram negative. Gram positive bacteria include pathogens such as *Staphylococcus aureus*, *Streptococcus pyogenes* and *Clostridium botulinum*. Gram negative bacteria include pathogens such as *Salmonella*, *Escherichia coli*, *Klebsiella*, *Haemophilus*, *Pseudomonas aeruginosa*, *Proteus* and *Shigella dysenteriae*. Gram negative bacteria are generally distinguished from Gram positive by an additional protective cell membrane which generally results in the Gram negative bacteria being less susceptible to topical antibacterial actives.

Antimicrobial cleansing products have been marketed in a variety of forms, for some time. Forms include antibacterial soaps, hard surface cleaners, and surgical disinfectants. Rinse-off antimicrobial soaps have been formulated to provide bacteria removal during washing. Antimicrobial liquid cleansers are disclosed in U.S. Patent Numbers: 4,847,072, Bissett et al.,

issued July 11, 1989, 4,939,284, Degenhardt, issued July 3, 1990 and 4,820,698, Degenhardt, issued April 11, 1989, all patents being incorporated herein by reference.

Some of these traditional products, especially the hard surface cleaners and surgical disinfectants, utilize high levels of alcohol and/or harsh surfactants which have been shown to dry out and irritate skin tissues. Ideal personal cleansers should gently cleanse the skin, cause little or no irritation, and not leave the skin overly dry after frequent use and preferably should provide a moisturizing benefit to the skin.

Finally, these traditional antimicrobial compositions have been developed for use in a washing process with water. This limits their use to locations with available water.

Cleansing wipes have been used, in the past, to wash hands and face while traveling or in public or anytime water is not available. In fact, consumers have used absorbent sheets impregnated with topical compositions for a variety of purposes. U.S. Patent Number 4,045,364, Richter, et al., issued August 30, 1977 teaches a dry disposable paper impregnated with a germicidal composition comprising an anionic surfactant, an elemental iodine or iodophor active ingredient and a weak acid for pH adjustment. The compositions utilize iodine actives which are not stable in the presence of substantial amounts of water and insufficient acid levels to provide the antimicrobial effectiveness of the present invention. European Patent Application, EP 0 619 074, Touchet et al., published October 12, 1994, teaches the use of sorbic or benzoic acids as antimicrobial agents in a wipe, however does not teach the anionic surfactant and separate antimicrobial active necessary to achieve the effectiveness of the present invention. U.S. Patent Number 4,975,217, Brown-Skrobot et al., issued December 4, 1990 teaches the use of anionic surfactants and organic acids on a wipe, however does not teach the use of the active required to provide the antimicrobial effectiveness benefits.

Currently marketed Nice'n Clean®, Wash'n Dry® and No More Germies® are all antibacterial wipes which utilize harsh cationic surfactants with no additional antibacterial active. These products do not provide the improved antimicrobial effectiveness and may be harsh to the skin.

PCT application WO 92/18100, Keegan et al., published October 29, 1992 and PCT application WO 95/32705, Fujiwara et al., published December 7, 1995 teach non-wipe liquid skin cleansers comprising mild surfactants, antibacterial agents and acidic compounds to buffer the pH, which provide improved germ hostility. However, the use of low levels of the acid compounds therein, results in compositions which do not deliver sufficient undissociated acid required to provide residual effectiveness versus Gram negative bacteria, or improved residual effectiveness versus Gram positive bacteria, or the improved immediate germ reduction of the present invention. This situation is compounded in Keegan and Fujiwara by the preference of

mild surfactants, including nonionic surfactants. Neither Keegan nor Fujiwara teach the use of their compositions in a form which can be used without available water, e.g. a wipe.

U.S. Patent Number 3,141,821, issued to Compeau, July 21, 1964 and Irgasan DP 300 (Triclosan®) technical literature from Ciba-Giegy, Inc., "Basic Formulation for Hand Disinfection 89/42/01" set forth antibacterial skin cleanser compositions which could provide improved residual effectiveness versus Gram positive bacteria using certain anionic surfactants, antimicrobial actives and acids. However, the selection of highly active surfactants results in personal cleansing compositions which are drying and harsh to the skin. Again, neither reference teaches the use of antimicrobial compositions in a form which can be used without available water, e.g. a wipe.

Given the health impacts of Gram negative bacteria like *Salmonella*, *Escherichia coli* and *Shigella* and of Gram positive bacteria like *Staphylococcus aureus*, *Streptococcus pyogenes* and *Clostridium botulinum*, it would be highly desirable to formulate antimicrobial cleansing products which provides previously unseen residual effectiveness versus these Gram negative bacteria, or which provide improved residual effectiveness versus these Gram positive bacteria, or which provide improved immediate germ reduction upon washing, and which are mild to the skin and which can be used without water. Existing products have been unable to deliver all of these benefits.

Applicants have found that antimicrobial wipes which provide such mildness and such antimicrobial effectiveness can be formulated by using known porous or absorbent sheets which are impregnated with improved antimicrobial cleansing compositions. These improved antimicrobial cleansing compositions contain antibacterial actives in combination with specific organic and/or inorganic acids as proton donating agents, and specific anionic surfactants, all of which are deposited on the skin. The deposited proton donating agent and anionic surfactant enhance the selected active, to provide a new level of hostility to bacteria contacting the skin.

SUMMARY OF THE INVENTION

The present invention relates to an antimicrobial wipe comprising a porous or absorbent sheet impregnated with an antimicrobial cleansing composition, wherein the antimicrobial cleansing composition comprises from 0.001% to 5.0%, by weight of the antimicrobial cleansing composition, of an antimicrobial active; from 0.05% to 10%, by weight of the antimicrobial cleansing composition, of an anionic surfactant; from 0.1% to 10%, by weight of the antimicrobial cleansing composition, of a proton donating agent; and from 3% to 99.85%, by weight of the antimicrobial cleansing composition, water; wherein the composition is adjusted to a pH of from 3.0 to 6.0; wherein the antimicrobial cleansing composition has a Gram Negative Residual Effectiveness Index of greater than 0.3. The present invention also relates to an

improved antimicrobial cleansing composition which also has a Mildness Index of greater than 0.3.

The present invention also relates to an antimicrobial wipe impregnated with an antimicrobial cleansing composition which has a Gram Positive Residual Effectiveness Index of greater than 0.5. It also relates to an antimicrobial wipe impregnated with an antimicrobial cleansing composition which has a One-wash Immediate Germ Reduction Index of greater than 1.3.

The present invention also relates to methods for cleansing and decreasing the spread of transient Gram positive bacteria using the antimicrobial wipes described herein.

DETAILED DESCRIPTION OF THE INVENTION

The antimicrobial wipes of the present invention are highly efficacious for providing residual antimicrobial effectiveness versus Gram negative bacteria, or residual antimicrobial effectiveness versus transient Gram positive bacteria, or an improved immediate germ reduction on the skin during cleansing; and are mild to the skin and can be used without additional available water.

The term "antimicrobial wipe" is used herein to mean products in which a sheet of porous or absorbent material have been impregnated with an antimicrobial cleansing composition for the purpose of rubbing the wipe product over a surface to clean the surface and control the growth and viability of transient bacteria. The term "antimicrobial cleansing composition" as used herein means a composition suitable for application to the human skin for the purpose of removing dirt, oil and the like, which additionally controls the growth and viability of transient bacteria on the skin.

By "residual effectiveness" it is meant that bacteria growth on a surface is controlled for some period of time following the washing/rinsing process.

The compositions of the present invention can also be useful for treatment of acne. As used herein "treating acne" means preventing, retarding and/or arresting the process of acne formation in mammalian skin.

The compositions of the invention can also be useful for providing an essentially immediate (i.e., acute) visual improvement in skin appearance following application of the composition to the skin. More particularly, the compositions of the present invention are useful for regulating skin condition, including regulating visible and/or tactile discontinuities in skin, including but not limited to visible and/or tactile discontinuities in skin texture and/or color, more especially discontinuities associated with skin aging. Such discontinuities may be induced or caused by internal and/or external factors. Extrinsic factors include ultraviolet radiation (e.g., from sun exposure), environmental pollution, wind, heat, low humidity, harsh surfactants,

abrasives, and the like. Intrinsic factors include chronological aging and other biochemical changes from within the skin.

Regulating skin condition includes prophylactically and/or therapeutically regulating skin condition. As used herein, prophylactically regulating skin condition includes delaying, minimizing and/or preventing visible and/or tactile discontinuities in skin. As used herein, therapeutically regulating skin condition includes ameliorating, e.g., diminishing, minimizing and/or effacing, such discontinuities. Regulating skin condition involves improving skin appearance and/or feel, e.g., providing a smoother, more even appearance and/or feel. As used herein, regulating skin condition includes regulating signs of aging. "Regulating signs of skin aging" includes prophylactically regulating and/or therapeutically regulating one or more of such signs (similarly, regulating a given sign of skin aging, e.g., lines, wrinkles or pores, includes prophylactically regulating and/or therapeutically regulating that sign).

"Signs of skin aging" include, but are not limited to, all outward visibly and tactilely perceptible manifestations as well as any other macro or micro effects due to skin aging. Such signs may be induced or caused by intrinsic factors or extrinsic factors, e.g., chronological aging and/or environmental damage. These signs may result from processes which include, but are not limited to, the development of textural discontinuities such as wrinkles, including both fine superficial wrinkles and coarse deep wrinkles, skin lines, crevices, bumps, large pores (e.g., associated with adnexal structures such as sweat gland ducts, sebaceous glands, or hair follicles), scaliness, flakiness and/or other forms of skin unevenness or roughness, loss of skin elasticity (loss and/or inactivation of functional skin elastin), sagging (including puffiness in the eye area and jowls), loss of skin firmness, loss of skin tightness, loss of skin recoil from deformation, discoloration (including undereye circles), blotching, sallowness, hyperpigmented skin regions such as age spots and freckles, keratoses, abnormal differentiation, hyperkeratinization, elastosis, collagen breakdown, and other histological changes in the stratum corneum, dermis, epidermis, the skin vascular system (e.g., telangiectasia or spider vessels), and underlying tissues, especially those proximate to the skin.

All percentages and ratios used herein, unless otherwise indicated, are by weight and all measurements made are at 25°C, unless otherwise designated. The invention hereof can comprise, consist of, or consist essentially of, the essential as well as optional ingredients and components described therein.

The antimicrobial wipes of the present invention comprise the following essential components.

A. THE POROUS OR ABSORBENT SHEET

The antimicrobial cleansing composition is impregnated at the desired weight onto one or both sides of an absorbent sheet (hereinafter sometimes referred to as "substrate") which may be

formed from any woven or nonwoven fiber, fiber mixture or foam of sufficient wet strength and absorbency to hold an effective amount of the antimicrobial cleansing composition. It is preferred from the standpoint of antimicrobial effectiveness and mildness to employ substrates with a high absorbent capacity (e.g., from 5 to 20 grams/gram, preferably from 9 to 20 grams/gram). The absorbent capacity of a substrate is the ability of the substrate, while supported horizontally, to hold liquid. The absorbent capacity of a substrate is measured according to the Absorbent Capacity Method set forth hereinafter in the Analytical Methods section.

In particular, woven or nonwoven fabrics derived from "oriented" or carded fibrous webs composed of textile-length fibers, the major proportion of which are oriented predominantly in one direction are suitable for use herein. These fabrics can be in the form of, for example, wipes or towelettes, including baby wipes and the like.

Methods of making woven and nonwoven cloths are not a part of this invention and, being well known in the art, are not described in detail herein. Generally, however, such cloths are made by air- or water-laying processes in which the fibers or filaments are first cut to desired lengths from long strands, passed into a water or air stream, and then deposited onto a screen through which the fiber-laden air or water is passed. The deposited fibers or filaments are then adhesively bonded together, and otherwise treated as desired to form the woven, nonwoven, or cellulose cloth.

Thermocarded nonwoven cloths (whether or not resin-containing) are made of polyesters, polyamides, or other thermoplastic fibers which can be spand bonded, i.e., the fibers are spun out onto a flat surface and bonded (melted) together by heat or chemical reactions.

The nonwoven cloth substrates used in the invention herein are generally adhesively bonded fibers or filamentous products having a web or carded fiber structure (when the fiber strength is suitable to allow carding) or comprising fibrous mats in which the fibers or filaments are distributed haphazardly or in random array (i.e., an array of fibers in a carded web where partial orientation of the fibers is frequently present, as well as a completely haphazard distributional orientation), or substantially aligned. The fibers or filaments can be natural (e.g., wool, silk, jute, hemp, cotton, linen, sisal, or ramie) or synthetic (e.g., rayon, cellulose ester, polyvinyl derivatives, polyolethins, polyamides, or polyesters) as have been described hereinabove. These nonwoven materials are generally described in Riedel "Nonwoven Bonding Methods and Materials", Nonwoven World, (1987).

The absorbent properties preferred herein are particularly easy to obtain with nonwoven cloths and are provided merely by building up the thickness of the cloth, i.e., by superimposing a plurality of carded webs or mats to a thickness adequate to obtain the necessary absorbent properties, or by allowing a sufficient thickness of the fibers to deposit on the screen. Any

denier of the fiber (generally up to 15 denier) can be used, inasmuch as it is the free space between each fiber that makes the thickness of the cloth directly related to the absorbent capacity of the cloth. Thus, any thickness necessary to obtain the required absorbent capacity can be used.

B. THE ANTIMICROBIAL CLEANSING COMPOSITION

The absorbent sheets used in the present invention are impregnated with an antimicrobial cleansing composition. The term "antimicrobial cleansing composition" as used herein means a composition suitable for application to a surface for the purpose of removing dirt, oil and the like which additionally controls the growth and viability of transient Gram positive bacteria. Preferred embodiments of the present invention are cleansing compositions suitable for use on the human skin.

I. INGREDIENTS

The antimicrobial cleansing compositions of the wipes of the present invention comprise an antimicrobial active, an anionic surfactant, and a proton donating agent. These components are selected so that the efficacy and optional mildness requirements hereinafter defined for the compositions herein are met. The selection of each component is necessarily dependent on the selection of each of the other components. For example, if a weak acid is selected as the proton donating agent, then in order to realize an efficacious composition, either a more biologically active (but possibly less mild) surfactant must be employed, and/or a high level of acid within the prescribed range must be used and/or a particularly efficacious active must be employed. Similarly, if a mild, but nonefficacious surfactant is employed, then a stronger acid and/or a high level of acid may be necessary to realize an efficacious composition. If a harsh surfactant is utilized, then a mildness agent may have to be utilized. Guidelines for the selection of the individual components are provided herein.

The Antimicrobial Active

The antimicrobial cleansing composition of the antimicrobial wipes of the present invention comprises from 0.001% to 5%, preferably from 0.05% to 1%, more preferably from 0.05% to 0.5% and more preferably from 0.1% to 0.25%, by weight of the antimicrobial cleansing composition, of an antimicrobial active. The exact amount of antibacterial active to be used in the compositions will depend on the particular active utilized since actives vary in potency. Non-cationic actives are required in order to avoid interaction with the anionic surfactants of the invention.

Given below are examples of non-cationic antimicrobial agents which are useful in the present invention .

Pyrithiones, especially the zinc complex (ZPT)

Octopirox®

Dimethyldimethylol Hydantoin (Glydant®)

Methylchloroisothiazolinone/methylisothiazolinone (Kathon CG®)
 Sodium Sulfite
 Sodium Bisulfite
 Imidazolidinyl Urea (Germall 115®)
 Diazolidinyl Urea (Germaill II®)
 Benzyl Alcohol
 2-Bromo-2-nitropropane-1,3-diol (Bronopol®)
 Formalin (formaldehyde)
 Iodopropenyl Butylcarbamate (Polyphase P100®)
 Chloroacetamide
 Methanamine
 Methyl dibromonitrile Glutaronitrile (1,2-Dibromo-2,4-dicyanobutane or Tektamer®)
 Glutaraldehyde
 5-bromo-5-nitro-1,3-dioxane (Bronidox®)
 Phenethyl Alcohol
 o-Phenylphenol/sodium o-phenylphenol
 Sodium Hydroxymethylglycinate (Suttocide A®)
 Polymethoxy Bicyclic Oxazolidine (Nuosept C®)
 Dimethoxane
 Thimersal
 Dichlorobenzyl Alcohol
 Captan
 Chlorphenenesin
 Dichlorophene
 Chlorbutanol
 Glyceryl Laurate
 Halogenated Diphenyl Ethers
 2,4,4'-trichloro-2'-hydroxy-diphenyl ether (Triclosan® or TCS)
 2,2'-dihydroxy-5,5'-dibromo-diphenyl ether
 Phenolic Compounds
 Phenol
 2-Methyl Phenol
 3-Methyl Phenol
 4-Methyl Phenol
 4-Ethyl Phenol
 2,4-Dimethyl Phenol
 2,5-Dimethyl Phenol
 3,4-Dimethyl Phenol
 2,6-Dimethyl Phenol
 4-n-Propyl Phenol
 4-n-Butyl Phenol
 4-n-Amyl Phenol
 4-tert-Amyl Phenol
 4-n-Hexyl Phenol
 4-n-Heptyl Phenol
 Mono- and Poly-Alkyl and Aromatic Halophenols
 p-Chlorophenol
 Methyl p-Chlorophenol
 Ethyl p-Chlorophenol
 n-Propyl p-Chlorophenol

n-Butyl p-Chlorophenol
 n-Amyl p-Chlorophenol
 sec-Amyl p-Chlorophenol
 n-Hexyl p-Chlorophenol
 Cyclohexyl p-Chlorophenol
 n-Heptyl p-Chlorophenol
 n-Octyl p-Chlorophenol
 o-Chlorophenol
 Methyl o-Chlorophenol
 Ethyl o-Chlorophenol
 n-Propyl o-Chlorophenol
 n-Butyl o-Chlorophenol
 n-Amyl o-Chlorophenol
 tert-Amyl o-Chlorophenol
 n-Hexyl o-Chlorophenol
 n-Heptyl o-Chlorophenol
 o-Benzyl p-Chlorophenol
 o-Benzyl-m-methyl p-Chlorophenol
 o-Benzyl-m, m-dimethyl p-Chlorophenol
 o-Phenylethyl p-Chlorophenol
 o-Phenylethyl-m-methyl p-Chlorophenol
 3-Methyl p-Chlorophenol
 3,5-Dimethyl p-Chlorophenol
 6-Ethyl-3-methyl p-Chlorophenol
 6-n-Propyl-3-methyl p-Chlorophenol
 6-iso-Propyl-3-methyl p-Chlorophenol
 2-Ethyl-3,5-dimethyl p-Chlorophenol
 6-sec-Butyl-3-methyl p-Chlorophenol
 2-iso-Propyl-3,5-dimethyl p-Chlorophenol
 6-Diethylmethyl-3-methyl p-Chlorophenol
 6-iso-Propyl-2-ethyl-3-methyl p-Chlorophenol
 2-sec-Amyl-3,5-dimethyl p-Chlorophenol
 2-Diethylmethyl-3,5-dimethyl p-Chlorophenol
 6-sec-Octyl-3-methyl p-Chlorophenol
 p-Chloro-m-cresol
 p-Bromophenol
 Methyl p-Bromophenol
 Ethyl p-Bromophenol
 n-Propyl p-Bromophenol
 n-Butyl p-Bromophenol
 n-Amyl p-Bromophenol
 sec-Amyl p-Bromophenol
 n-Hexyl p-Bromophenol
 Cyclohexyl p-Bromophenol
 o-Bromophenol
 tert-Amyl o-Bromophenol
 n-Hexyl o-Bromophenol
 n-Propyl-m,m-Dimethyl o-Bromophenol
 2-Phenyl Phenol
 4-Chloro-2-methyl phenol

4-Chloro-3-methyl phenol
 4-Chloro-3,5-dimethyl phenol
 2,4-Dichloro-3,5-dimethylphenol
 3,4,5,6-Tetrabromo-2-methylphenol
 5-Methyl-2-pentylphenol
 4-Isopropyl-3-methylphenol
 Para-chloro-meta-xenol (PCMX)
 Chlorothymol
 Phenoxyethanol
 Phenoxyisopropanol
 5-Chloro-2-hydroxydiphenylmethane

Resorcinol and its Derivatives

Resorcinol
 Methyl Resorcinol
 Ethyl Resorcinol
 n-Propyl Resorcinol
 n-Butyl Resorcinol
 n-Amyl Resorcinol
 n-Hexyl Resorcinol
 n-Heptyl Resorcinol
 n-Octyl Resorcinol
 n-Nonyl Resorcinol
 Phenyl Resorcinol
 Benzyl Resorcinol
 Phenylethyl Resorcinol
 Phenylpropyl Resorcinol
 p-Chlorobenzyl Resorcinol
 5-Chloro 2,4-Dihydroxydiphenyl Methane
 4'-Chloro 2,4-Dihydroxydiphenyl Methane
 5-Bromo 2,4-Dihydroxydiphenyl Methane
 4' -Bromo 2,4-Dihydroxydiphenyl Methane

Bisphenolic Compounds

2,2'-Methylene bis (4-chlorophenol)
 2,2'-Methylene bis (3,4,6-trichlorophenol)
 2,2'-Methylene bis (4-chloro-6-bromophenol)
 bis (2-hydroxy-3,5-dichlorophenyl) sulphide
 bis (2-hydroxy-5-chlorobenzyl)sulphide

Benzoic Esters (Parabens)

Methylparaben
 Propylparaben
 Butylparaben
 Ethylparaben
 Isopropylparaben
 Isobutylparaben
 Benzylparaben
 Sodium Methylparaben
 Sodium Propylparaben

Halogenated Carbanilides

3,4,4'-Trichlorocarbanilides (Triclocarban® or TCC)
 3-Trifluoromethyl-4,4'-dichlorocarbanilide

3,3',4-Trichlorocarbanilide

Another class of antibacterial agents, which are useful in the present invention, are the so-called "natural" antibacterial actives, referred to as natural essential oils. These actives derive their names from their natural occurrence in plants. Typical natural essential oil antibacterial actives include oils of anise, lemon, orange, rosemary, wintergreen, thyme, lavender, cloves, hops, tea tree, citronella, wheat, barley, lemongrass, cedar leaf, cedarwood, cinnamon, fleagrass, geranium, sandalwood, violet, cranberry, eucalyptus, vervain, peppermint, gum benzoin, basil, fennel, fir, balsam, menthol, oregano, *Hydastis carradensis*, *Berberidaceae daceae*, *Ratanhia* and *Curcuma longa*. Also included in this class of natural essential oils are the key chemical components of the plant oils which have been found to provide the antimicrobial benefit. These chemicals include, but are not limited to anethol, catechole, camphene, carvacol, eugenol, eucalyptol, ferulic acid, farnesol, hinokitiol, tropolone, limonene, menthol, methyl salicylate, thymol, terpineol, verbenone, berberine, ratanhia extract, caryophellene oxide, citronellic acid, curcumin, nerolidol and geraniol.

Additional active agents are antibacterial metal salts. This class generally includes salts of metals in groups 3b-7b, 8 and 3a-5a. Specifically are the salts of aluminum, zirconium, zinc, silver, gold, copper, lanthanum, tin, mercury, bismuth, selenium, strontium, scandium, yttrium, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium and mixtures thereof.

Preferred antimicrobial agents for use herein are the broad spectrum actives selected from the group consisting of Triclosan®, Triclocarban®, Octopirox®, PCMX, ZPT, natural essential oils and their key ingredients, and mixtures thereof. The most preferred antimicrobial active for use in the present invention is Triclosan®.

Anionic Surfactant

The antimicrobial cleansing compositions of the present invention comprise from 0.05% to 10, preferably from 0.1 to 2%, and more preferably from 0.2% to 1%, by weight of the cleansing composition, of an anionic surfactant. Without being limited by theory, it is believed that the anionic surfactant disrupts the lipid in the cell membrane of the bacteria. The particular acid used herein reduces the negative charges on the cell wall of the bacteria, crosses through the cell membrane, weakened by the surfactant, and acidifies the cytoplasm of the bacteria. The antimicrobial active can then pass more easily through the weakened cell wall, and more efficiently poison the bacteria.

Nonlimiting examples of anionic lathering surfactants useful in the compositions of the present invention are disclosed in McCutcheon's, Detergents and Emulsifiers, North American edition (1990), published by The Manufacturing Confectioner Publishing Co.; McCutcheon's, Functional Materials, North American Edition (1992); and U.S. Patent No. 3,929,678, to Laughlin et al., issued December 30, 1975, all of which are incorporated by reference.

A wide variety of anionic surfactants are potentially useful herein. Nonlimiting examples of anionic lathering surfactants include those selected from the group consisting of alkyl and alkyl ether sulfates, sulfated monoglycerides, sulfonated olefins, alkyl aryl sulfonates, primary or secondary alkane sulfonates, alkyl sulfosuccinates, acyl taurates, acyl isethionates, alkyl glycerylether sulfonate, sulfonated methyl esters, sulfonated fatty acids, alkyl phosphates, acyl glutamates, acyl sarcosinates, alkyl sulfoacetates, acylated peptides, alkyl ether carboxylates, acyl lactylates, anionic fluorosurfactants, and mixtures thereof. Mixtures of anionic surfactants can be used effectively in the present invention.

Anionic surfactants for use in the cleansing compositions include alkyl and alkyl ether sulfates. These materials have the respective formulae R^1O-SO_3M and $R^1(CH_2H_4O)_x-O-SO_3M$, wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl group from 8 to 24 carbon atoms, x is 1 to 10, and M is a water-soluble cation such as ammonium, sodium, potassium, magnesium, triethanolamine, diethanolamine and monoethanolamine. The alkyl sulfates are typically made by the sulfation of monohydric alcohols (having from 8 to 24 carbon atoms) using sulfur trioxide or other known sulfation technique. The alkyl ether sulfates are typically made as condensation products of ethylene oxide and monohydric alcohols (having from 8 to 24 carbon atoms) and then sulfated. These alcohols can be derived from fats, e.g., coconut oil or tallow, or can be synthetic. Specific examples of alkyl sulfates which may be used in the cleanser compositions are sodium, ammonium, potassium, magnesium, or TEA salts of lauryl or myristyl sulfate. Examples of alkyl ether sulfates which may be used include ammonium, sodium, magnesium, or TEA laureth-3 sulfate.

Another suitable class of anionic surfactants are the sulfated monoglycerides of the form $R^1CO-O-CH_2-C(OH)H-CH_2-O-SO_3M$, wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl group from 8 to 24 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium, magnesium, triethanolamine, diethanolamine and monoethanolamine. These are typically made by the reaction of glycerin with fatty acids (having from 8 to 24 carbon atoms) to form a monoglyceride and the subsequent sulfation of this monoglyceride with sulfur trioxide. An example of a sulfated monoglyceride is sodium cocomonoglyceride sulfate.

Other suitable anionic surfactants include olefin sulfonates of the form R^1SO_3M , wherein R^1 is a mono-olefin having from 12 to 24 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium, magnesium, triethanolamine, diethanolamine and monoethanolamine. These compounds can be produced by the sulfonation of alpha olefins by means of uncomplexed sulfur trioxide, followed by neutralization of the acid reaction mixture in conditions such that any sulfones which have been formed in the reaction are hydrolyzed to give the corresponding hydroxyalkanesulfonate. An example of a sulfonated olefin is sodium C_{14} - C_{16} alpha olefin sulfonate.

Other suitable anionic surfactants are the linear alkylbenzene sulfonates of the form $R^1-C_6H_4-SO_3M$, wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl group from 8 to 24 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium, magnesium, triethanolamine, diethanolamine and monoethanolamine. These are formed by the sulfonation of linear alkyl benzene with sulfur trioxide. An example of this anionic surfactant is sodium dodecylbenzene sulfonate.

Still other anionic surfactants suitable for this cleansing composition include the primary or secondary alkane sulfonates of the form R^1SO_3M , wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl chain from 8 to 24 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium, magnesium, triethanolamine, diethanolamine and monoethanolamine. These are commonly formed by the sulfonation of paraffins using sulfur dioxide in the presence of chlorine and ultraviolet light or another known sulfonation method. The sulfonation can occur in either the secondary or primary positions of the alkyl chain. An example of an alkane sulfonate useful herein is alkali metal or ammonium C_{13} - C_{17} paraffin sulfonates.

Still other suitable anionic surfactants are the alkyl sulfosuccinates, which include disodium N-octadecylsulfosuccinamate; diammonium lauryl sulfosuccinate; tetrasodium N-(1,2-dicarboxyethyl)-N-octadecylsulfosuccinate; diamyl ester of sodium sulfosuccinic acid; dihexyl ester of sodium sulfosuccinic acid; and dioctyl esters of sodium sulfosuccinic acid.

Also useful are taurates which are based on taurine, which is also known as 2-aminoethanesulfonic acid. Examples of taurates include N-alkyltaurines such as the one prepared by reacting dodecylamine with sodium isethionate according to the teaching of U.S. Patent 2,658,072 which is incorporated herein by reference in its entirety. Other examples based of taurine include the acyl taurines formed by the reaction of n-methyl taurine with fatty acids (having from 8 to 24 carbon atoms).

Another class of anionic surfactants suitable for use in the cleansing composition are the acyl isethionates. The acyl isethionates typically have the formula $R^1CO-O-CH_2CH_2SO_3M$ wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl group having from 10 to 30 carbon atoms, and M is a cation. These are typically formed by the reaction of fatty acids (having from 8 to 30 carbon atoms) with an alkali metal isethionate. Nonlimiting examples of these acyl isethionates include ammonium cocoyl isethionate, sodium cocoyl isethionate, sodium lauroyl isethionate, and mixtures thereof.

Still other suitable anionic surfactants are the alkylglyceryl ether sulfonates of the form $R^1-OCH_2-C(OH)H-CH_2-SO_3M$, wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl group from 8 to 24 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium, magnesium, triethanolamine, diethanolamine and monoethanolamine. These can be formed by the reaction of epichlorohydrin and sodium bisulfite with fatty alcohols (having from 8 to 24 carbon atoms) or other known methods. One example is sodium cocoglyceryl ether sulfonate.

Other suitable anionic surfactants include the sulfonated fatty acids of the form $R^1-CH(SO_4)-COOH$ and sulfonated methyl esters of the form $R^1-CH(SO_4)-CO-O-CH_3$, where R^1 is a saturated or unsaturated, branched or unbranched alkyl group from 8 to 24 carbon atoms. These can be formed by the sulfonation of fatty acids or alkyl methyl esters (having from 8 to 24 carbon atoms) with sulfur trioxide or by another known sulfonation technique. Examples include alpha sulphonated coconut fatty acid and lauryl methyl ester.

Other anionic materials include phosphates such as monoalkyl, dialkyl, and trialkylphosphate salts formed by the reaction of phosphorous pentoxide with monohydric branched or unbranched alcohols having from 8 to 24 carbon atoms. These could also be formed by other known phosphorylation methods. An example from this class of surfactants is sodium mono or dilaurylphosphate.

Other anionic materials include acyl glutamates corresponding to the formula $R^1CO-N(COOH)-CH_2CH_2-CO_2M$ wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl or alkenyl group of 8 to 24 carbon atoms, and M is a water-soluble cation. Nonlimiting examples of which include sodium lauroyl glutamate and sodium cocoyl glutamate.

Other anionic materials include alkanoyl sarcosinates corresponding to the formula $R^1\text{CON}(\text{CH}_3)\text{-CH}_2\text{CH}_2\text{-CO}_2\text{M}$ wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl or alkenyl group of 10 to 20 carbon atoms, and M is a water-soluble cation. Nonlimiting examples of which include sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, and ammonium lauroyl sarcosinate.

Other anionic materials include alkyl ether carboxylates corresponding to the formula $R^1\text{-(OCH}_2\text{CH}_2)_x\text{-OCH}_2\text{-CO}_2\text{M}$ wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl or alkenyl group of 8 to 24 carbon atoms, x is 1 to 10, and M is a water-soluble cation. Nonlimiting examples of which include sodium laureth carboxylate.

Other anionic materials include acyl lactylates corresponding to the formula $R^1\text{CO-[O-CH(CH}_3\text{)-CO]}_x\text{-CO}_2\text{M}$ wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl or alkenyl group of 8 to 24 carbon atoms, x is 3, and M is a water-soluble cation. Nonlimiting examples of which include sodium cocoyl lactylate.

Other anionic materials include the carboxylates, nonlimiting examples of which include sodium lauroyl carboxylate, sodium cocoyl carboxylate, and ammonium lauroyl carboxylate. Anionic fluorsurfactants can also be used.

Any counter cation, M, can be used on the anionic surfactant. Preferably the counter cation is selected from the group consisting of sodium, potassium, ammonium, monoethanolamine, diethanolamine, and triethanolamine. More preferably the counter cation is ammonium.

Two factors must be taken into account when selecting the surfactant or surfactants to be employed in the antibacterial cleansing compositions of the antimicrobial wipes herein: 1) the activity of the surfactant molecule at the cell membrane of the bacteria; and 2) the mildness of the surfactant insofar as it affects the Mildness Index (hereinafter described) for the antibacterial composition.

Biological Activity/Mildness of Surfactant

In general, the higher the biological activity of the surfactant, the more residual effectiveness is provided by the composition comprising the surfactant. Typically, however, the biological activity of a surfactant and the mildness of a surfactant are inversely proportional; the higher the biological activity of the surfactant, the harsher the surfactant and the lower the biological activity of the surfactant, the milder the surfactant. Whether a biologically active, but harsh surfactant or a mild, but biologically inactive surfactant is desired will, of course, depend on (or influence) the selection of the other components.

The biological activity/mildness of a pure surfactant can be measured directly via a Microtox Response Test hereinafter described in the Analytical Methods section and can be reported as a Microtox Response Index. By "pure surfactant" it is meant a chemical composition consisting

essentially of a single surfactant entity, wherein the entity has essentially one chain length, head group and salt counter ion. From a standpoint of high biological activity, preferred anionic surfactants of the antimicrobial cleansing compositions of the present invention have a Microtox Response Index of less than 150, more preferably less than 100 and most preferably less than 50. From a standpoint of mildness, preferred anionic surfactants of the antimicrobial cleansing compositions of the present invention have a Microtox Response Index of greater than 25, more preferably greater than 50 and most preferably greater than 100. Surfactants with a Microtox Response Index ranging from 25 to 150 are typically moderately biologically active and moderately mild.

For surfactant compositions which are mixtures of surfactants rather than pure surfactants (this includes "commercial grade" surfactants which typically comprise mixtures of entities with different chain lengths and potentially have higher levels of impurities), the Microtox Response Index for any individual surfactant component is not a reliable measurement of biological activity or mildness. In the case of mixtures, the Microtox Index of each individual component can be determined and the weighted average used as the Index for the mixture if all the individual components of the mixture are known. If the individual components of a mixture are not known, then the primary head group and chain lengths of the surfactant mixture are better indicators of biological activity/mildness.

Anionic surfactants or mixtures of surfactants with a chain length primarily in the range of from 8 to 24 carbon atoms, preferably primarily from 10 to 18 carbon atoms and most preferably primarily from 12 to 16 carbon atoms are preferred from the standpoint of high biological activity. As used herein "primarily" means at least 50%. From a standpoint of mildness, it is preferable to minimize C12.

From the standpoint of biological activity, it is preferred that the head group of the anionic surfactant be less than 15 Angstroms, preferably less than 10 Angstroms, and more preferably less than 7 Angstroms. The "head group" is defined as the hydrophilic portion (non-hydrocarbon) of the anionic surfactant, measured from the first polar atom to the end of the molecule. The head group size is estimated from the Van der Waals radius of the atoms and the configuration of the surfactant molecule. Head groups with sizes less than 7 Angstroms include sulfates, sulfonates, and phosphates. From the standpoint of mildness, it is preferred that the head group size is greater than 7 Angstroms, and preferably greater than 10 Angstroms. Head groups with sizes greater than 10 Angstroms include ethoxylated sulfates, glyceryl ether sulfonates, and isethionates. It is believed that as the head group size increases, more stearic hindrance at the cell wall prevents disruption by the surfactant and, thus, biological activity is decreased and mildness is increased.

The mildness of a surfactant or mixture of surfactants can also be determined by a number of other known, conventional methods for measuring surfactant mildness. For example, the Barrier Destruction Test set forth in T. J. Franz, *J. Invest. Dermatol.*, 1975, 64, pp. 190-195 and in U.S. Patent 4,673,525 to Small et al; issued June 16, 1987, both of which are herein incorporated by reference, is a way of measuring mildness of surfactants. In general, the milder the surfactant, the less skin barrier that is destroyed in the barrier destruction test. Skin barrier destruction is measured by relative amount of radiolabeled water which passes from the test solution through the skin epidermis into the physiological buffer contained in the diffusate chamber. Surfactants having a Relative Skin Barrier Penetration Value of as close to zero as possible up to 75 are considered mild for purposes herein. Surfactants having a Relative Skin Barrier Penetration Value of greater than 75 are considered harsh for purposes herein.

In order for the antimicrobial composition of the antimicrobial wipes herein to be effective, both the biological activity of the surfactant and the mildness of the surfactant and acid employed in the composition must be taken into account.

For example, ammonium lauryl sulfate, ALS, is very biologically active (Microtox Index = 1.0). Compositions comprising ALS are capable of providing very effective residual antibacterial effectiveness due to its activity, even with lower levels of antibacterial active and proton donating agent. However, compositions containing ALS may require the addition of co-surfactants or polymers, described herein in the Optional Ingredient Section, to achieve most preferred mildness levels for the present invention.

A selection of ammonium laureth-3 sulfate (Microtox = 120) as a surfactant will result in compositions which are very mild, but which would require higher levels of proton donating agent and antimicrobial active in order to achieve the residual effectiveness of the present invention.

Paraffin sulfonate, a commercial grade surfactant sold under the name Hastapur SAS® from Hoechst Celanese, with a small head group and average chain length of 15.5 is a relatively active surfactant. Compositions comprising lower levels of active and acid can be used with higher levels of paraffin sulfonate, where the surfactant provides a larger component of residual effectiveness. Alternately, compositions comprising lower levels of paraffin sulfonate can be combined with even higher levels of active to achieve a mild and effective composition.

Nonlimiting examples of preferred anionic surfactants useful herein include those selected from the group consisting of sodium and ammonium alkyl sulfates and ether sulfates having chain lengths of predominantly 12 and 14 carbon atoms, olefin sulfates having chain lengths of predominantly 14 and 16 carbon atoms, and paraffin sulfonates having chain lengths of from 13 to 17 carbon atoms, and mixtures thereof. Especially preferred for use herein is ammonium and sodium lauryl sulfate, ammonium and sodium myristyl sulfate, ammonium and sodium laureth-1

to laureth-4 sulfate, C14-C16 olefin sulfonates, C13-C17 paraffin sulfonates, and mixtures thereof.

Non-anionic surfactants of the group consisting of cationic surfactants, amphoteric surfactants and mixtures thereof, have been found to actually inhibit residual effectiveness benefits. It is believed that these surfactants interfere with the anionic surfactant disruption of the lipid in the cell membrane. The ratio of the amount of these non-anionic surfactants to the amount of anionic surfactant should be less than 1:1, preferably less than 1:2, and more preferably less than 1:4.

The antimicrobial cleansing compositions of the present invention preferably do not comprise hydrotropic sulfonates, particularly salts of terpenoids, or mono- or binuclear aromatic compounds such as sulfonates of camphor, toluene, xylene, cumene and naphthene.

Proton Donating Agent

The antimicrobial cleansing compositions of the present invention comprise from 0.1% to 10%, preferably from 0.5% to 8%, more preferably from 1% to 5%, based on the weight of the personal cleansing composition, of a proton donating agent. By "proton donating agent" it is meant any acid compound or mixture thereof, which results in undissociated acid on the skin after use. Proton donating agents can be organic acids, including polymeric acids, mineral acids or mixtures thereof.

Organic Acids

Proton donating agents which are organic acids which remain at least partially undissociated in the neat composition and remain so when the compositions are diluted during washing and rinsing. These organic proton donating agents can be added directly to the composition in the acid form or can be formed by adding the conjugate base of the desired acid and a sufficient amount of a separate acid strong enough to form the undissociated acid from the base.

Buffering Capacity

Preferred organic proton donating agents are selected and formulated based on their buffer capacity and pKa. Buffer capacity is defined as the amount of protons (weight %) available in the formulation at the product pH for those acid groups with pKa's less than 6.0. Buffer capacity can be either calculated using pKa's, pH, and the concentrations of the acids and conjugate bases, ignoring any pKa greater than 6.0, or it can be determined experimentally through a simple acid-base titration using sodium hydroxide or potassium hydroxide using an endpoint of pH equals 6.0.

Preferred organic proton donating agents of the antibacterial cleansing composition herein have a buffer capacity of greater than 0.005%, more preferably greater than 0.01%, even more preferably greater than 0.02%, and most preferably greater than 0.04%.

Mineral Acids

Proton donating agents which are mineral acids will not remain undissociated in the neat composition and when the compositions are diluted during washing and rinsing. Despite this, it has been found that mineral acids can be effective proton donating agents for use herein. Without being limited by theory, it is believed that the strong mineral acid, acidify the carboxylic and phosphatidyl groups in proteins of the skin cells, thereby providing *in-situ* undissociated acid. These proton donating agents can only be added directly to the composition in the acid form.

pH

It is critical to achieving the benefits of the invention that the undissociated acid from the proton donating agent (deposited or formed *in-situ*) remain on the skin in the protonated form. Therefore, the pH of the antimicrobial cleansing compositions of the present invention must be adjusted to a sufficiently low level in order to either form or deposit substantial undissociated acid on the skin. The pH of the compositions should be adjusted and preferably buffered to range from 3.0 to 6.0, preferably from 3.0 to 5.0 and more preferably from 3.5 to 4.5.

A non-exclusive list of examples of organic acids which can be used as the proton donating agent are adipic acid, tartaric acid, citric acid, maleic acid, malic acid, succinic acid, glycolic acid, glutaric acid, benzoic acid, malonic acid, salicylic acid, gluconic acid, polymeric acids, their salts, and mixtures thereof. A non-exclusive list of examples of mineral acid for use herein are hydrochloric, phosphoric, sulfuric and mixtures thereof.

Polymeric acids are especially preferred acids for use herein from the standpoint that they cause less stinging to the skin than other acids. As used herein, the term "polymeric acid" refers to an acid with repeating units of carboxylic acid groups joined together into one chain. Suitable polymeric acids can include homopolymers, copolymers and terpolymers, but must contain at least 30 mole% carboxylic acid groups. Specific examples of suitable polymeric

acids useful herein include straight-chain poly(acrylic) acid and its copolymers, both ionic and nonionic, (e.g., maleic-acrylic, sulfonic-acrylic, and styrene-acrylic copolymers), those cross-linked polyacrylic acids having a molecular weight of less than 250,000, preferably less than 100,000 poly (α -hydroxy) acids, poly (methacrylic) acid, and naturally occurring polymeric acids such as carageenic acid, carboxy methyl cellulose, and alginic acid. Straight-chain poly(acrylic) acids are especially preferred for use herein.

Water

The antimicrobial cleansing compositions of the present invention comprise from 3% to 98.899%, preferably from 5% to 98%, more preferably from 10% to 97.5%, and most preferably from 38% to 95.99% water.

Preferable Optional Ingredients

Mildness Enhancers

In order to achieve the mildness required of the present invention, optional ingredients to enhance the mildness to the skin can be added. These ingredients include cationic and nonionic polymers, co-surfactants, moisturizers and mixtures thereof. Polymers useful herein include polyethylene glycols, polypropylene glycols, hydrolyzed silk proteins, hydrolyzed milk proteins, hydrolyzed keratin proteins, guar hydroxypropyltrimonium chloride, polyquats, silicone polymers and mixtures thereof. When used, the mildness enhancing polymers comprise from 0.1% to 1%, preferably from 0.2% to 1.0%, and more preferably from 0.2% to 0.6%, by weight of the antimicrobial cleansing composition, of the composition. Co-surfactants useful herein include nonionic surfactants such as the Genapol® 24 series of ethoxylated alcohols, POE(20) sorbitan monooleate (Tween® 80), polyethylene glycol cocoate and Pluronic® propylene oxide/ethylene oxide block polymers, and amphoteric surfactants such as alkyl betaines, alkyl sultaines, alkyl amphotacetates, alkyl amphodiacetates, alkyl amphopropionates, and alkyl amphodipropionates. When used, the mildness enhancing cosurfactants comprise from 20% to 70%, preferably from 20% to 50%, by weight of the anionic surfactant, of the cleansing composition.

Another group of mildness enhancers are lipid skin moisturizing agents which provide a moisturizing benefit to the user of the cleansing wipe when the lipophilic skin moisturizing agent is deposited to the user's skin. When used in the antimicrobial personal cleansing compositions herein, lipophilic skin moisturizing agents are used, they are employed at a level of 0.1% to 30%, preferably from 0.2% to 10%, most preferably from 0.5% to 5% by weight of the composition.

In some cases, the lipophilic skin moisturizing agent can desirably be defined in terms of its solubility parameter, as defined by Vaughan in Cosmetics and Toiletries, Vol. 103, p. 47-69, October 1988. A lipophilic skin moisturizing agent having a Vaughan solubility Parameter

(VSP) from 5 to 10, preferably from 5.5 to 9 is suitable for use in the antimicrobial cleansing compositions herein.

A wide variety of lipid type materials and mixtures of materials are suitable for use in the antimicrobial cleansing compositions of the present invention. Preferably, the lipophilic skin conditioning agent is selected from the group consisting of hydrocarbon oils and waxes, silicones, fatty acid derivatives, cholesterol, cholesterol derivatives, di- and tri-glycerides, vegetable oils, vegetable oil derivatives, liquid nondigestible oils such as those described in U.S. Patents 3,600,186 to Mattson; Issued August 17, 1971 and 4,005,195 and 4,005,196 to Jandacek et al; both issued January 25, 1977, all of which are herein incorporated by reference, or blends of liquid digestible or nondigestible oils with solid polyol polyesters such as those described in U.S. Patent 4,797,300 to Jandacek; issued January 10, 1989; U.S Patents 5,306,514, 5,306,516 and 5,306,515 to Letton; all issued April 26, 1994, all of which are herein incorporated by reference, and acetoglyceride esters, alkyl esters, alkenyl esters, lanolin and its derivatives, milk tri-glycerides, wax esters, beeswax derivatives, sterols, phospholipids and mixtures thereof. Fatty acids, fatty acid soaps and water soluble polyols are specifically excluded from our definition of a lipophilic skin moisturizing agent.

- Hydrocarbon oils and waxes: Some examples are petrolatum, mineral oil microcrystalline waxes, polyalkenes (e.g. hydrogenated and nonhydrogenated polybutene and polydecene), paraffins, cerasin, ozokerite, polyethylene and perhydrosqualene. Blends of petrolatum and hydrogenated and nonhydrogenated high molecular weight polybutenes wherein the ratio of petrolatum to polybutene ranges from 90:10 to 40:60 are also suitable for use as the lipid skin moisturizing agent in the compositions herein.

Silicone Oils: Some examples are dimethicone copolyol, dimethylpolysiloxane, diethylpolysiloxane, high molecular weight dimethicone, mixed C1-C30 alkyl polysiloxane, phenyl dimethicone, dimethiconol, and mixtures thereof. More preferred are non-volatile silicones selected from dimethicone, dimethiconol, mixed C1-C30 alkyl polysiloxane, and mixtures thereof. Nonlimiting examples of silicones useful herein are described in U.S. Patent No. 5,011,681, to Ciotti et al., issued April 30, 1991, which is incorporated by reference.

Di- and tri-glycerides: Some examples are castor oil, soy bean oil, derivatized soybean oils such as maleated soy bean oil, safflower oil, cotton seed oil, corn oil, walnut oil, peanut oil, olive oil, cod liver oil, almond oil, avocado oil, palm oil and sesame oil, vegetable oils and vegetable oil derivatives; coconut oil and derivatized coconut oil, cottonseed oil and derivatized cottonseed oil, jojoba oil, cocoa butter, and the like.

Acetoglyceride esters are used and an example is acetylated monoglycerides.

Lanolin and its derivatives are preferred and some examples are lanolin, lanolin oil, lanolin wax, lanolin alcohols, lanolin fatty acids, isopropyl lanolate, acetylated lanolin, acetylated lanolin alcohols, lanolin alcohol linoleate, lanolin alcohol riconoleate.

It is most preferred when at least 75 % of the lipophilic skin conditioning agent is comprised of lipids selected from the group consisting: petrolatum, blends of petrolatum and high molecular weight polybutene, mineral oil, liquid nondigestible oils (e.g. liquid cottonseed sucrose octaesters) or blends of liquid digestible or nondigestible oils with solid polyol polyesters (e.g. sucrose octaesters prepared from C22 fatty acids) wherein the ratio of liquid digestible or nondigestible oil to solid polyol polyester ranges from 96:4 to 80:20, hydrogenated or nonhydrogenated polybutene, microcrystalline wax, polyalkene, paraffin, cerasin, ozokerite, polyethylene, perhydrosqualene; dimethicones, alkyl siloxane, polymethylsiloxane, methylphenylpolysiloxane and mixtures thereof. When as blend of petrolatum and other lipids is used, the ratio of petrolatum to the other selected lipids (hydrogenated or unhydrogenated polybutene or polydecene or mineral oil) is preferably from 10:1 to 1:2, more preferably from 5:1 to 1:1.

Stabilizers

When a lipophilic skin moisturizing agent is employed as the mildness enhancer in the antimicrobial compositions herein, a stabilizer may also be included at a level ranging from 0.1% to 10%, preferably from 0.1% to 8%, more preferably from 0.1% to 5% by weight of the antimicrobial cleansing composition.

The stabilizer is used to form a crystalline stabilizing network in the liquid cleansing composition that prevents the lipophilic skin moisturizer agent droplets from coalescing and phase splitting in the product. The network exhibits time dependent recovery of viscosity after shearing (e.g., thixotropy).

The stabilizers used herein are not surfactants. The stabilizers provide improved shelf and stress stability. Some preferred hydroxyl-containing stabilizers include 12-hydroxystearic acid, 9,10-dihydroxystearic acid, tri-9,10-dihydroxystearin and tri-12-hydroxystearin (hydrogenated castor oil is mostly tri-12-hydroxystearin). Tri-12-hydroxystearin is most preferred for use in the compositions herein. When these crystalline, hydroxyl-containing stabilizers are utilized in the cleansing compositions herein, they are typically present at from 0.1% to 10%, preferably from 0.1% to 8%, more preferably from 0.1% to 5% of the antimicrobial cleansing compositions. The stabilizer is insoluble in water under ambient to near ambient conditions.

Alternatively, the stabilizer employed in the cleansing compositions herein can comprise a polymeric thickener. When polymeric thickeners as the stabilizer in the cleansing compositions herein, they are typically included in an amount ranging from 0.01% to 5%, preferably from 0.3% to 3%, by weight of the composition. The polymeric thickener is

preferably an anionic, nonionic, cationic or hydrophobically modifier polymer selected from the group consisting of cationic polysaccharides of the cationic guar gum class with molecular weights of 1,000 to 3,000,000, anionic cationic and nonionic homopolymers derived from acrylic and/or methacrylic acid, anionic, cationic, and nonionic cellulose resins, cationic copolymers of dimethyldialkylammonium chloride, and acrylic acid, cationic homopolymers of dimethylalkylammonium chloride, cationic polyalkylene, and ethoxypolyalkylene imines, polyethylene glycol of molecular weight from 100,000 to 4,000,000, and mixtures thereof. Preferably, the polymer is selected from the group consisting of sodium polyacrylate, hydroxy ethyl cellulose, cetyl hydroxy ethyl cellulose, and Polyquaternium 10.

Alternatively, the stabilizer employed in the cleansing compositions herein can comprise C10-C22 ethylene glycol fatty acid esters. C10-C22 ethylene glycol fatty acid esters can also desirably be employed in combination with the polymeric thickeners hereinbefore described. The ester is preferably a diester, more preferably a C14-C18 diester, most preferably ethylene glycol distearate. When C10-C22 ethylene glycol fatty acid esters are utilized as the stabilizer in the personal cleansing compositions herein, they are typically present at from 3% to 10%, preferably from 5% to 8%, more preferably from 6% to 8% of the personal cleansing compositions.

Another class of stabilizer which can be employed in the antimicrobial cleansing compositions of the present invention comprises dispersed amorphous silica selected from the group consisting of fumed silica and precipitated silica and mixtures thereof. As used herein the term "dispersed amorphous silica" refers to small, finely divided non-crystalline silica having a mean agglomerate particle size of less than 100 microns.

Fumed silica, which is also known as arced silica, is produced by the vapor phase hydrolysis of silicon tetrachloride in a hydrogen oxygen flame. It is believed that the combustion process creates silicone dioxide molecules which condense to form particles. The particles collide, attach and sinter together. The result of this process is a three dimensional branched chain aggregate. Once the aggregate cools below the fusion point of silica, which is 1710°C, further collisions result in mechanical entanglement of the chains to form agglomerates. Precipitated silicas and silica gels are generally made in aqueous solution. See, Cabot Technical Data Pamphlet TD-100 entitled "CAB-O-SIL® Untreated Fumed Silica Properties and Functions", October 1993, and Cabot Technical Data Pamphlet TD-104 entitled "CAB-O-SIL® Fumed Silica in Cosmetic and Personal Care Products", March 1992, both of which are herein incorporated by reference.

The fumed silica preferably has a mean agglomerate particle size ranging from 0.1 microns to 100 microns, preferably from 1 micron to 50 microns, and more preferably from 10 microns to 30 microns. The agglomerates are composed of aggregates which have a mean

particle size ranging from 0.01 microns to 15 microns, preferably from 0.05 microns to 10 microns, more preferably from 0.1 microns to 5 microns and most preferably from 0.2 microns to 0.3 microns. The silica preferably has a surface area greater than 50 sq. m./gram, more preferably greater than 130 sq. m./gram, most preferably greater than 180 sq. m./gram.

When amorphous silicas are used as the stabilizer herein, they are typically included in the cleansing compositions at levels ranging from 0.1% to 10%, preferably from 0.25% to 8%, more preferably from 0.5% to 5%.

A fourth class of stabilizer which can be employed in the antimicrobial cleansing compositions of the present invention comprises dispersed smectite clay selected from the group consisting of bentonite and hectorite and mixtures thereof. Bentonite is a colloidal aluminum clay sulfate. See Merck Index, Eleventh Edition, 1989, entry 1062, p. 164, which is incorporated by reference. Hectorite is a clay containing sodium, magnesium, lithium, silicon, oxygen, hydrogen and fluorine. See Merck Index, eleventh Edition, 1989, entry 4538, p. 729, which is herein incorporated by reference.

When smectite clay is employed as the stabilizer in the cleansing compositions of the present invention, it is typically included in amounts ranging from 0.1% to 10%, preferably from 0.25% to 8%, more preferably from 0.5% to 5%.

Other known stabilizers, such as fatty acids and fatty alcohols, can also be employed in the compositions herein. Palmitic acid and lauric acid are especially preferred for use herein.

Other Optional Ingredients

The compositions of the present invention can comprise a wide range of optional ingredients. The CTFA International Cosmetic Ingredient Dictionary, Sixth Edition, 1995, which is incorporated by reference herein in its entirety, describes a wide variety of nonlimiting cosmetic and pharmaceutical ingredients commonly used in the skin care industry, which are suitable for use in the compositions of the present invention. Nonlimiting examples of functional classes of ingredients are described at page 537 of this reference. Examples of these functional classes include: abrasives, anti-acne agents, anticaking agents, antioxidants, binders, biological additives, bulking agents, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, emulsifiers, external analgesics, film formers, fragrance components, humectants, opacifying agents, plasticizers, preservatives, propellants, reducing agents, skin bleaching agents, skin-conditioning agents (emollient, humectants, miscellaneous, and occlusive), skin protectants, solvents, foam boosters, hydrotropes, solubilizing agents, suspending agents (nonsurfactant), sunscreen agents, ultraviolet light absorbers, and viscosity increasing agents (aqueous and nonaqueous). Examples of other functional classes of materials useful herein that are well known to one of ordinary skill in the art include solubilizing agents, sequestrants, and keratolytics, and the like.

II. CHARACTERISTICS

The antimicrobial cleansing compositions of the antimicrobial wipes herein, have the following characteristics.

A. BACTERIAL EFFECTIVENESS

The rinse of antimicrobial cleansing compositions of the present invention have one of three characteristics of bacterial effectiveness.

Gram Negative Residual Effectiveness Index

The antimicrobial cleansing compositions of the present invention have a Gram Negative Residual Effectiveness Index of greater than 0.3 (50% reduction), preferably greater than 1.0 (90% reduction), and more preferably greater than 2.0 (99% reduction). The Gram Negative Residual Effectiveness Index is measured by the *In-Vivo* Residual Effectiveness on *Escherichia coli* Test described hereinafter in the Analytical Methods Section. The index represents a difference in base ten logarithm values of bacterial concentrations between a test sample and a control. For example, an index of 0.3 represents a reduction in log values of 0.3 ($\Delta\log = 0.3$) which in turn represents a 50% reduction of bacteria counts.

Gram Positive Residual Effectiveness Index

The antimicrobial cleansing compositions of the present invention comprise a Gram Positive Residual Effectiveness Index of greater than 0.5 (68% reduction), preferably greater than 1.0 (90.0% reduction), more preferably greater than 2.0 (99% reduction), and most preferably greater than 2.3 (99.5% reduction). The Gram Positive Residual Effectiveness Index is measured by the *In-Vivo* Residual Effectiveness on *Staphylococcus aureus* Test described herein. The index represents a difference in base ten logarithm values of bacterial concentrations between a test sample and a placebo control. For example, an index of 0.5 represents a reduction in log values of 0.5 ($\Delta\log = 0.5$) which in turn represents a 68% reduction of bacteria counts.

Immediate Germ Reduction Indexes

The antimicrobial wipes provide improved immediate reduction of germs on the skin. The degree of reduction can be measured after one-wash of the *In-Vivo* Health Care Personal Handwash Test described herein. When measured after one wash (application) the antimicrobial wipe has One-wash Immediate Germ Reduction Index of greater than 1.3 (95% reduction), preferably greater than 1.7 (98% reduction), more preferably greater than 2.0 (99% reduction), and most preferably greater than 2.3 (99.5% reduction). The index represents a difference in base ten logarithm values of bacterial concentrations between before and after washing. For example, an index of 1.3 represents a reduction in log values of 1.3 ($\Delta\log = 1.3$) which in turn represents a 95% reduction of bacteria counts.

B. Mildness Index

The antimicrobial cleansing compositions of the present invention comprise a Mildness Index of greater than 0.3, preferably greater than 0.4, and more preferably greater than 0.6. The Mildness Index is measured by the Forearm Controlled Application Test (FCAT) described herein.

III. PREPARATION OF THE ABSORBENT SHEETS IMPREGNATED WITH ANTIMICROBIAL CLEANSING COMPOSITION

Any method suitable for the application of aqueous or aqueous/alcoholic impregnates, including flood coating, spray coating or metered dosing, can be used to impregnate the fibrous webs herein with the antimicrobial cleansing compositions described herein. More specialized techniques, such as Meyer Rod, floating knife or doctor blade, which are typically used to impregnate liquids into absorbent sheets may also be used.

The emulsion should preferably comprise from 100% to 400%, preferably from 200% to 400% by weight of the absorbent sheet.

After coating, the sheets may be folded into stacks and packaged in any of the moisture and vapor impermeable packages known in the art.

The anti-microbial cleansing compositions of the present invention are made via art recognized techniques for the various forms compositions.

IV. METHODS OF USING THE ANTIMICROBIAL WIPES

The antimicrobial wipe of the present invention are useful for personal cleansing and providing residual effectiveness versus Gram positive bacteria, especially on the hands and face. Typically the wipe is used to apply cleansing compositions to the area to be cleansed. The wipes herein can be used for personal cleansing when the use of cleansing products requiring water cannot be, or are inconvenient. Typical quantities of the present wipes useful for cleansing, range from 1 to 4 wipes per use, preferably from 1 to 2 wipes per use. Typical amounts of antimicrobial cleansing composition used range from 4 mg/cm² to 6 mg/cm², preferably 5 mg.cm² of skin area to be cleansed.

ANALYTICAL TEST METHODS

MICROTOX RESPONSE TEST

Reference: Microtox Manual: A Toxicity Testing Handbook, 1992

Volume I-IV; Microbics Corporation.

Equipment: Microtox M500 Toxicity Testing Unit; Microbics Corporation

Connected to computer for data acquisition and analysis according to above reference.

Procedure:

1. Preparation of Sample Stock Solution (Standard Concentration: 1000 ppm)

The stock solution of the test anionic surfactant sample is prepared and used as a stock solution from which all other dilutions are made. The standard "starting concentration", the highest concentration to be tested, is 500 ppm. (If a 500 ppm starting concentration fails to give a calculable result, e.g. an active surfactant kills all reagent at all dilutions, the starting concentration can be adjusted based on a known range of EC50 values of previously tested surfactants.) The stock solution is prepared at two times the starting concentration.

- a) Add 0.1g (or adjusted amount if required) of anionic surfactant, accounting for activity of raw material, to beaker.
- b) Microtox Diluent (2% NaCl, Microbics Corp.) is added to total 100g.
- c) Stir solution to make sure of adequate mixing.

2. Reconstitution of Microtox Reagent and Preparation of Assay

- a) Turn on test unit and allow reagent well temperature to equilibrate at 5.5°C and incubator block and read well temperature to equilibrate at 15°C.
- b) Place a clean cuvette (Microbics Corp.) in the reagent well, and fill with 1.0 ml of Microtox Reconstitution Solution (distilled water, Microbics, Corp.). Allow to cool for 15 minutes.
- c) Reconstitute standard vial of Microtox Acute Toxicity Reagent (*Vibrio fischeri*, Microbics Corp.) by quickly adding the 1.0 ml of the cooled reconstitution solution to the reagent vial.
- d) Swirl solution in the reagent vial for 2-3 seconds then pour reconstituted reagent back into the cooled cuvette and return the vial to the reagent well. Allow to stabilize for 15 minutes.
- e) Place 8 cuvettes containing 500 µl of Microtox Diluent, as assay, into the incubator wells of the test unit. Let cool for 15 minutes.

3. Test Substance Dilution

Prepare 7 serial dilutions of the test substance from the sample stock solution. The final volume of all cuvettes must be 1.0 ml.

- a) Place 8 empty cuvettes into a test tube rack.
- b) Add 1.0 ml of Microtox Diluent solution to tubes 1-7.
- c) Add 2.0 ml of the sample stock solution (1000 ppm) in cuvette 8.
- d) Transfer 1.0 ml solution from cuvette 8 to cuvette 7 and mix cuvette 7.
- e) Serially transfer 1.0 ml from the newly formed solution to the subsequent cuvette (7 to 6, 6 to 5 etc.). Remove 1.0 ml of solution from cuvette 2 and discard. Cuvette 1 is the blank containing only Microtox Diluent. Place the cuvettes into the test unit incubation

wells keeping them in order of lowest to highest concentration. These cuvettes should correspond with the 8 cuvettes prepared in step 2 above. Allow to cool for 15 minutes.

4. Assay and Sample Bioluminescence Testing

- a) Add 10 µl of reconstituted reagent to the 8 precooled cuvettes of assay prepared in step 2 above (containing 500 µl of diluent). Allow 15 minutes for reagent to stabilize.
- b) Start Microtox Data Capture and Reporting Software (Microbics Corp.), select START TESTING, input file name and description, correct starting concentration in ppm (500 if standard concentration is used) and number of controls (1) and dilutions (7). Time 1 should be selected as 5 minutes, time 2 is NONE. Press enter then the space bar to begin testing.
- c) Place the assay cuvette containing reagent which corresponds to the test blank into the read well and press SET. After the cuvette has resurfaced press READ and the value will be captured by the computer.
- d) Similarly read the remaining 7 cuvettes containing reagent when prompted by the computer by pressing the READ button with the correct cuvette in the READ well.
- e) After all 8 initial reading have been taken, transfer 500 µl of the diluted test substance into their corresponding cuvette containing the reagent. Mix by vortexing or swirling and return to the incubation wells. The computer will count for five minutes and prompt you to begin final readings.
- f) Take final readings by placing the correct cuvette containing reagent and diluted test surfactant into the read well and pressing READ when prompted by the computer.

5. Data Analysis

The concentration of test substance, in ppm, that decreases the bioluminescence of the Microtox Acute Toxicity Reagent by 50% from the starting value (EC50 Value) can be calculated using the *Run Statistics on Data File* option of the Microtox Software (recommended) or by conducting a linear regression of the data (% reduction vs. log of concentration). % Reductions are calculated using the following formulas:

$$\frac{\text{Final Reading of Reagent Blank}}{\text{Initial Reading of Reagent Blank}} = \text{Correction Factor}$$

$$\frac{\text{Final Reading of Reagent with Diluted Test Substance}}{\text{Initial Reading of Reagent with Diluted Test Substance}} = \text{Reduction Factor}_x$$

where x means at a corresponding concentration

$$\% \text{ Reduction} = \frac{\text{Correction Factor}_x - \text{Reduction Factor}}{\text{Correction Factor}}$$

The Microtox Index is the EC50 value in ppm.

IN VIVO RESIDUAL EFFECTIVENESS ON *E.coli*

References: Aly, R; Maibach, H.I.; Aust, L.B.; Corbin, N.C.; Finkey, M.B. 1994.

1. *In vivo effect of antimicrobial soap bars containing 1.5% and 0.8% trichlorocarbanilide against two strains of pathogenic bacteria.* J. Soc. Cosmet. Chem., 35, 351-355, 1981.
2. *In vivo methods for testing topical antimicrobial agents.* J. Soc. Cosmet. Chem., 32, 317-323.

1. Test Design

Residual Antibacterial efficacy of liquid and bar soap antimicrobial products are quantified in the following method. Reductions are reported from a control, non-antibacterial placebo soap, without further treatment, used on one of the subjects forearms. By definition the antibacterial placebo will show no residual effectiveness in the test.

2. Pre-Test Phase

Subjects are instructed not to use antibacterial products for 7 days prior to testing. Immediately before test, the subjects hands are examined for cuts/broken skin that would preclude them from participating.

3. Wash Procedure for Wipes Test Product

- a) Wash both forearms with placebo soap one time to remove any contaminants or transient bacteria. Rinse and dry forearms.
- b) Test monitor marks 10cm x 5cm treatment area on forearm.
- c) Test monitor wipes the treatment site with appropriate wipe in an up-and-down motion for 10 seconds.
- d) Arm is allowed to air dry and test sites are marked (~8.6 cm² circle with rubber stamp).
- e) Mark site with stamp on other forearm of subject for placebo product evaluation.

4. Inoculation Procedure

- a) *E. coli* inoculum (ATCC 10536, grown from lyophilized stock in Soybean-casein broth at 37C for 18-24 hrs) is adjusted to approximately 10⁸ organisms/ml (0.45 transmittance vs. TSB blank on spectrophotometer).
- b) Each test site is inoculated with 10 µl of *E. coli*. Inoculum is spread with inoculating loop into a ~3 cm² circle and covered with a Hilltop Chamber (Hilltop Research Inc.).
- c) This procedure is repeated for each test site on each forearm.

5. Sampling Bacteria (Extraction Procedure)

- a) Prepare sampling solution of 0.04% KH_2PO_4 , 1.01% Na_2HPO_4 , 0.1% Triton X-100, 1.5% Polysorbate 80, 0.3% Lecithin in water, adjusted to pH 7.8 with 1 N HCl.
- b) Exactly 60 minutes after inoculation, the Hilltop Chamber is removed from the site from which a sample is to be taken. A 8.6 cm^2 sampling cup is placed over the site
- c) 5 ml of sampling solution is added to the cup.
- d) Extract the bacteria by gently rubbing site with glass police man for 30 seconds.
- e) Remove sampling solution with pipette and place in a sterile labeled test tube.
- f) Repeat extraction with 5 ml of sampling fluid. This entire extraction procedure is repeated for each site 60 minutes after inoculation.

6. Quantifying Bacteria

- a) Prepare phosphate buffer solution of 0.117% Na_2HPO_4 , 0.022% NaH_2PO_4 , and 0.85% NaCl adjusted to pH 7.2-7.4 with 1 N HCl.
- b) 1.1 ml of the sampling solution is aseptically removed from the tube, 0.1 ml of the solution is spread plated onto trypticase-soy agar containing 1.5% Polysorbate 80. Remaining 1 ml is placed into 9 ml of sterile phosphate buffer achieving a 1:10 dilution of the sampling solution. This process is repeated 3 more times (each serial dilution).
- c) The plates are inverted and incubated for 24 hours at 35C.
- d) Colonies formed on plates are then enumerated and results are calculated by multiplying the counts by the dilution factor (original sample = 10, first dilution = 100, second dilution = 1000, etc.) and the final results are reported as the number of colony forming units per ml (CFU's/ml).

7. Index Calculation

Gram Negative Residual Efficacy Index =

$$\log_{10} (\text{CFU's/ml of placebo site}) - \log_{10} (\text{CFU's/ml of test product site})$$

IN VIVO RESIDUAL EFFECTIVENESS ON *Staphylococcus aureus*

References: Aly, R; Maibach, H.I.; Aust, L.B.; Corbin, N.C.; Finkey, M.B. 1994.

1. *In vivo effect of antimicrobial soap bars containing 1.5% and 0.8% trichlorocarbanilide against two strains of pathogenic bacteria.* J. Soc. Cosmet. Chem., 35, 351-355, 1981.
2. *In vivo methods for testing topical antimicrobial agents.* J. Soc. Cosmet. Chem., 32, 317-323.

1. Test Design

Residual Antibacterial efficacy of liquid and bar soap antimicrobial products are quantified in the following method. Reductions are reported from a control, non-

antibacterial placebo soap, without further treatment, used on one of the subjects forearms. By definition the antibacterial placebo will show no residual effectiveness in the test.

2. Pre-Test Phase

Subjects are instructed not to use antibacterial products for 7 days prior to testing. Immediately before test, the subjects hands are examined for cuts/broken skin that would preclude them from participating.

3. Wash Procedure for Wipes Test Product

- a) Wash both forearms with placebo soap one time to remove any contaminants or transient bacteria. Rinse and dry forearms.
- b) Test monitor marks 10cm x 5cm treatment area on forearm.
- c) Test monitor wipes the treatment site with appropriate wipe in an up-and-down motion for 10 seconds.
- d) Arm is allowed to air dry and test sites are marked ($\sim 8.6 \text{ cm}^2$ circle with rubber stamp).
- e) Mark site with stamp on other forearm of subject for placebo product evaluation.

4. Inoculation Procedure

- a) *S. aureus* inoculum (ATCC 27217, grown from lyophilized stock in Soybean-casein broth at 37C for 18-24 hrs) is adjusted to approximately 10^8 organisms/ml (0.45 transmittance vs. TSB blank on spectrophotometer).
- b) Each test site is inoculated with 10 μl of *S. aureus*. Inoculum is spread with inoculating loop into a $\sim 3 \text{ cm}^2$ circle and covered with a Hilltop Chamber (Hilltop Research Inc.).
- c) This procedure is repeated for each test site on each forearm.

5. Sampling Bacteria (Extraction Procedure)

- a) Prepare sampling solution of 0.04% KH_2PO_4 , 1.01% Na_2HPO_4 , 0.1% Triton X-100, 1.5% Polysorbate 80, 0.3% Lecithin in water, adjusted to pH 7.8 with 1 N HCl.
- b) Exactly 60 minutes after inoculation, the Hilltop Chamber is removed from the site from which a sample is to be taken. A 8.6 cm^2 sampling cup is placed over the site.
- c) 5 ml of sampling solution is added to the cup.
- d) Extract the bacteria by gently rubbing site with glass police man for 30 seconds.
- e) Remove sampling solution with pipette and place in a sterile labeled test tube.
- f) Repeat extraction with 5 ml of sampling fluid. This entire extraction procedure is repeated for each site 60 minutes after inoculation.

6. Quantifying Bacteria

- a) Prepare phosphate buffer solution of 0.117% Na_2HPO_4 , 0.022% NaH_2PO_4 , and 0.85% NaCl adjusted to pH 7.2-7.4 with 1 N HCl.

- b) 1.1 ml of the sampling solution is aseptically removed from the tube, 0.1 ml of the solution is spread plated onto trypticase-soy agar containing 1.5% Polysorbate 80 . Remaining 1 ml is placed into 9 ml of sterile phosphate buffer achieving a 1:10 dilution of the sampling solution. This process is repeated 3 more times (each serial dilution).
- c) The plates are inverted and incubated for 24 hours at 35C.
- d) Colonies formed on plates are then enumerated and results are calculated by multiplying the counts by the dilution factor (original sample = 10, first dilution = 100, second dilution = 1000, etc.) and the final results are reported as the number of colony forming units per ml (CFU's/ml).

7. Index Calculation

Gram Positive Residual Efficacy Index =

$$\log_{10} (\text{CFU's/ml of placebo site}) - \log_{10} (\text{CFU's/ml of test product site})$$

IN-VIVO HEALTH CARE PERSONAL HANDWASH TEST (HCPHWT)

Reference: Annual Book of ASTM Standards, Vol. 11.05; ASTM Designation: E 1174 - 94;

"Standard Test Method for Evaluation of Health Care Personnel Handwash Formulation"

1. The test method used is identical to the method explained in this reference with the following changes/clarifications.
 - a. Testing on a subject was finished after the one wash extraction, when only one-wash data was desired. The test requires at least four subjects to be valid.
 - b. Historical Data was used as a control in this protocol. (i.e. a control soap was not run in every test)
 - c. Test Materials
 - Organism: *Serratia marcescens* ATCC 14756 (incubated 18-24 hrs. at 25C in soybean casein broth, adjusted to $\sim 10^8$ organisms/ml by diluting to 0.45 transmittance with a spectrophotometer)
 - Dilution Fluid: phosphate buffer (0.1% Triton X-100, 0.3% Lecithin, 1.5% Tween 80) adjusted to pH 7.2 with 1 N HCl
 - Agar: Soybean casein agar with 1.5% polysorbate 80
 - d. Application Procedure

Laboratory technical places wipe in subject's hand. Subject then wipes his/her entire hand with wipe for fifteen (15) seconds, wiping palm, back of hand, fingers and web areas between fingers, cuticles, and nail beds. Repeat the process for wiping of other hand. Discard wipe. Hands are not dried.

- e. Bacteria were enumerated by performing serial dilutions (1:10) of inoculum or extracted samples and spreading 0.1 ml of dilution on plates. Results are reported as the log reduction of bacteria from baseline.

One - wash Immediate Germ Reduction Index = $\text{Log (CFU's in Baseline Extraction)} - \text{Log (CFU's in Post - One Wash Extraction)}$

Ten - wash Immediate Germ Reduction Index = $\text{Log (CFU's in Baseline Extraction)} - \text{Log (CFU's in Post - Ten Wash Extraction)}$

- e. Hands were decontaminated by submersion in 70% ethanol for 15 sec. and then a five minute wash with control soap and water.

FOREARM CONTROLLED APPLICATION TEST (FCAT)

Reference: Ertel, K. D., et al.; "A Forearm Controlled Application Technique for Estimating the Relative Mildness of Personal Cleansing Products"; J. Soc. Cosmet. Chem. 46 (1995) 67-76

The Forearm Controlled Application Test, or FCAT, is a comparative test which discriminates differences in product mildness to the skin. A test product is compared to a standard soap based cleansing bar control.

Test Group Restrictions

Test groups of 20-30 subjects, 18 to 55 years of age, who regularly wash with soap are used. Potential subjects who (1) have an initial dryness grade of 3.0 or higher on the forearms as assessed during the initial examination, (2) have skin cancer, eczema, or psoriasis on the forearms, (3) are receiving injectable insulin, (4) are pregnant or lactating, or (5) are receiving treatment for skin problems or contact allergy are excluded. Subjects are to avoid hot tubs, swimming, and sun lamps, and to refrain from applying any soaps, cleansing products, creams, or gels to their forearms for the duration of the study. Subjects are to keep water off their forearms for at least two hours before the grading process. The studies are executed using a blinded, random product order format. Clinical assistant should verify the correct treatment sequence and document such before washing each subject.

Products are applied to the forearms a total of nine (9) times: two (2) times each day on the first four (4) days of the study and one (1) time on the final day. Visits to the test facility for washing must be spaced by a minimum of three (3) hours.

All clinical assistants must wear disposable gloves during wash procedure, rinsing them between treatments, and changing between subjects.

Control Product

The control product is a rolled bar soap containing:

| | |
|-------|------------------|
| 56.1% | Sodium Tallowate |
| 18.7% | Sodium Cocoate |
| 0.7% | Sodium Chloride |

| | |
|------|------------------------------|
| 24% | Water |
| 0.5% | Minors (Perfume, Impurities) |

Product Application Procedure

Both test and control products are tested on the same arm. The following test procedure is used.

1. The subject wets the entire surface of his/her volar forearm with 95-100°F tap water by holding the arm briefly under running tap water.
2. A clinical assistant wets one-quarter sheet (approximately 8" x 6") of Masslinn® towel with tap water, then squeezes the towel gently to remove excess water.
3. A clinical assistant applies the products to the arm, beginning with the product designated for the site nearest the elbow, using the appropriate procedure as follows:

Liquid Product

- a. Dispense 0.10 cc of test product from a syringe into the center of the appropriate marked area.
- b. Wet two fingers of gloved (latex) hand under the running tap (index and middle fingers).
- c. Move wetted fingers in a circular motion over the application site for 10 seconds to lather product.
- d. Lather remains on the application site for 90 seconds, then is rinsed off with running tap water for 15 seconds, taking care not to wash lather off the adjacent sites. After 10 seconds of the rinse has expired, the Clinical Assistant will gently rub the site being rinsed with her two gloved fingers for the remaining 5 seconds of the rinse.

Bar Product

- a. Wet two fingers of gloved (latex) hand under the running tap (index and middle fingers).
- b. Wet bar by holding bar briefly under running tap water. Test bars must be wet under a running tap at the start of each day.
- c. Rub wetted fingers in a circular motion, over the surface of the bar, for 15 seconds to form lather on bar and fingers.
- d. Rub the lathered fingers on the application site in a circular motion for 10 seconds to lather product on the skin.
- e. Lather remains on the application site for 90 seconds, then is rinsed off with running tap water for 15 seconds, taking care not to wash lather off the adjacent sites. After 10 seconds of the rinse has expired, the Clinical Assistant will gently rub the site being rinsed with her two gloved fingers for the remaining 5 seconds of the rinse..

Wipe Products

- a. Fold wipe in half, crosswise, and gently rub the wipe in a curricular motion within the appropriate area.
- b. Allow site to air dry for 90 seconds. Do not rinse site.

Leave-on Product

- a. Dispense 0.10 cc of test product from a syringe into the center of the appropriate marked area.
 - b. Move gloved fingers in a circular motion over the application site for 10 seconds.
 - c. Allow site to air dry for 90 seconds. Do not rinse site.
4. While waiting for the 90 second residence time to expire, the above procedure will be repeated on the remaining application site on that arm, working down the arm toward the wrist.
 5. Steps 1-4 are repeated on the appropriate test areas so two applications of product are made to test areas.
 6. After all of the application areas have two applications of products, the clinical assistant gently pats the subject's arm dry with a disposable paper towel.

Evaluation

The skin on each treatment area is evaluated by an expert grader at baseline and three hours after the final study wash. The treatment areas are evaluated under 2.75x magnification (model KFM-1A Luxo Illuminated Magnifying Lamp, Marshall Industries, Dayton, OH) with controlled lighting (General Electric Cool White, 22-watt, 8" Circuline fluorescent bulb).

The skin is evaluated by an expert grader, for dryness and a rating is assigned based on the definitions set forth below.

Table 1

Forearm Grading Scale

| Rating | Skin Dryness |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| 0 | No dryness |
| 1.0 | Patches of slight powderiness and occasional patches of small scales may be seen. |
| 2.0 | Generalized slight powderiness. Early cracking or occasional small lifting scales may be present. |
| 3.0 | Generalized moderate powderiness and/or heavy cracking and lifting scales. |
| 4.0 | Generalized heavy powderiness and/or heavy cracking and lifting scales. |
| 5.0 | Generalized high cracking and lifting scales. Eczematous change may be present. Powderiness may be present but not prominent. May see bleeding crack. |
| 6.0 | Generalized severe cracking. Eczematous change may be present. Bleeding cracks may be present. Scales large, may be beginning to disappear. |

The FCAT generally produces only mild to moderate skin irritation; however, if a treated site reaches a rating of 5.0 or greater, at any time during the study, treatment of all sites on that subject should be discontinued.

Data

After all subjects have been evaluated at the end of the test, the following values are determined:

R_{c0} = The average rating of control product area at baseline

R_{cf} = The average rating of control product area at test end

R_{t0} = The average rating of test product area at baseline

R_{tf} = The average rating of test product area at test end.

There are many external conditions which could influence the FCAT, such as relative humidity and water softness. The test is valid only if sufficient response is observed in the skin to the control product. The control response must be greater than 1.0 (i.e., $R_{cf} - R_{c0} \geq 1.0$) for the test to be valid.

Given a valid test, the Mildness Index of the test product is the difference in the skin responses to two products.

$$\text{Mildness Index} = (R_{cf} - R_{c0}) - (R_{tf} - R_{t0})$$

CONSISTENCY (k) AND SHEAR INDEX (n) OF THE LIPOPHILIC SKIN MOISTURIZING AGENT

The Carrimed CSL 100 Controlled Stress Rheometer is used to determine Shear Index, n, and Consistency, k, of the lipophilic skin moisturizing agent used herein. The determination is performed at 35°C with the 4 cm 2° cone measuring system typically set with a 51 micron gap and is performed via the programmed application of a shear stress (typically from 0.06 dynes/sq. cm to 5,000 dynes/sq. cm) over time. If this stress results in a deformation of the sample, i.e. strain of the measuring geometry of at least 10-4 rad/sec, then this rate of strain is reported as a shear rate. These data are used to create a viscosity μ Vs. shear rate γ' flow curve for the material. This flow curve can then be modeled in order to provide a mathematical expression that describes the material's behavior within specific limits of shear stress and shear rate. These results were fitted with the following well accepted power law model (see for instance: Chemical Engineering, by Coulson and Richardson, Pergamon, 1982 or Transport Phenomena by Bird, Stewart and Lightfoot, Wiley, 1960):

$$\text{Viscosity, } \mu = k (\gamma')^{n-1}$$

VISCOSITY OF THE ANTIMICROBIAL CLEANSING COMPOSITION

The Wells-Brookfield Cone/Plate Model DV-II+ Viscometer is used to determine the viscosity of the antimicrobial cleansing compositions herein. The determination is performed at 25°C with the 2.4 cm² cone (Spindle CP-41) measuring system with a gap of 0.013 mm between the two small pins on the respective cone and plate. The measurement is performed by injecting 0.5 ml of the sample to be analyzed between the cone and plate and rotating the cone at a set speed of 1 rpm. The resistance to the rotation of the cone produces a torque that is proportional to the shear stress of the liquid sample. The amount of torque is read and computed by the viscometer into absolute centipoise units (mPa's) based on geometric constants of the cone, the rate of rotation, and the stress related torque.

ABSORBENT CAPACITY

Substrate samples are placed in a temperature and relative humidity-controlled location for at least 2 hours prior to testing (temperature= 73°F ± 2°F, relative humidity 50% ± 2%).

A full size substrate sheet is supported horizontally in a tared filament lined basket and weighed to provide the weight of the dry sheet. The filament lined basket has crossed filaments which serve to support the sheet horizontally. The crossed filaments permit unrestricted movement of water into and out of the substrate sheet.

The substrate sheet, still supported in the basket, is lowered into a distilled water bath having a temperature of 73°F ± 2°F for one minute. The basket is then raised from the bath and the substrate sheet is allowed to drain for 1 minute. The basket and sheet are then re-weighed to obtain the weight of the water absorbed by the substrate sheet.

The Absorbent Capacity, in grams/gram, is calculated by dividing the weight of the water absorbed by the sheet by the weight of the dry sheet. the Absorbent Capacity is reported as an average of at least 8 measurements.

EXAMPLES

The following examples further describe and demonstrate embodiments within the scope of the present invention. In the following examples, all ingredients are listed at an active level. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention, as many variations thereof are possible without departing from the spirit and scope of the invention.

Ingredients are identified by chemical or CTFA name.

Fifteen antimicrobial cleansing compositions are prepared according to the tables below.

Antimicrobial Cleansing Compositions

| <u>Component</u> | <u>Ex. 1</u> | <u>Ex. 2</u> | <u>Ex. 3</u> | <u>Ex. 4</u> | <u>Ex. 5</u> |
|------------------|--------------|--------------|--------------|--------------|--------------|
| Mineral oil | 1.00% | 1.00% | 1.00% | 1.00% | 0.00% |
| Propylene glycol | 1.00% | 1.00% | 1.00% | 1.00% | 1.00% |

| | | | | | |
|--------------------------------------------|-------|-------|-------|-------|-------|
| Ammonium Lauryl Sulfate | 0.60% | 0.60% | 0.60% | 0.60% | 0.60% |
| Citric Acid | 4.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Sodium Citrate | 3.30% | 0.00% | 2.00% | 0.00% | 0.00% |
| Succinic Acid | 0.00% | 4.00% | 0.00% | 0.00% | 4.00% |
| Sodium Succinate | 0.00% | 3.30% | 0.00% | 0.00% | 3.20% |
| Malic Acid | 0.00% | 0.00% | 2.50% | 0.00% | 0.00% |
| Malonic Acid | 0.00% | 0.00% | 0.00% | 4.00% | 0.00% |
| Sodium Malonate | 0.00% | 0.00% | 0.00% | 3.20% | 0.00% |
| Steareth 20 | 0.55% | 0.55% | 0.55% | 0.55% | 0.00% |
| Steareth 2 | 0.45% | 0.45% | 0.45% | 0.45% | 0.00% |
| Triclosan® | 0.15% | 0.15% | 0.15% | 0.15% | 0.15% |
| Miscellaneous | 0.36% | 0.36% | 0.36% | 0.36% | 0.36% |
| Water | q.s. | q.s. | q.s. | q.s. | q.s. |
| pH | 4.0 | 4.5 | 3.9 | 3.9 | 3.9 |
| Microtox of Anionic Surfactant | 1 | 1 | 1 | 1 | 1 |
| Head Group Size of Anionic Surfactant | Small | Small | Small | Small | Small |
| Primary Chain Length of Anionic Surfactant | 12 | 12 | 12 | 12 | 12 |

| <u>Component</u> | <u>Ex. 6</u> | <u>Ex. 7</u> | <u>Ex. 8</u> | <u>Ex. 9</u> | <u>Ex.10</u> | <u>Ex. 10a</u> |
|----------------------------------------|--------------|--------------|--------------|--------------|--------------|----------------|
| Mineral oil | 0.00% | 0.00% | 1.00% | 1.00% | 1.00% | 1.00% |
| Propylene glycol | 1.00% | 1.00% | 1.00% | 1.00% | 1.00% | 1.00% |
| Ammonium Lauryl Sulfate | 0.60% | 0.60% | 0.60% | 0.60% | 1.00% | 0.60% |
| Citric Acid | 0.00% | 0.00% | 2.50% | 2.50% | 4.00% | 0.00% |
| Sodium Citrate | 0.00% | 3.70% | 2.00% | 2.00% | 3.20% | 0.00% |
| Succinic Acid | 4.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Sodium Succinate | 3.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Malic Acid | 0.00% | 4.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| polyacrylic acid/sodium polyacrylate * | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.5% |
| Steareth 20 | 0.55% | 0.00% | 0.55% | 0.08% | 0.28% | 0.08% |
| Steareth 2 | 0.45% | 0.00% | 0.45% | 0.07% | 0.23% | 0.07% |
| Oleth 20 | 0.00% | 0.00% | 0.00% | 0.08% | 0.28% | 0.08% |
| Oleth 2 | 0.00% | 0.00% | 0.00% | 0.07% | 0.23% | 0.07% |
| Triclosan® | 0.00% | 0.50% | 0.50% | 0.15% | 0.25% | 0.15% |
| Thymol | 1.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |

| | | | | | | |
|--------------------------------------------|-------|-------|-------|-------|-------|-------|
| Miscellaneous | 0.36% | 0.36% | 0.36% | 0.36% | 0.36% | 0.36% |
| Water | q.s. | q.s. | q.s. | q.s. | q.s. | q.s. |
| pH | 3.2 | 5.0 | 3.9 | 3.9 | 3.9 | 3.8 |
| Microtox of Anionic Surfactant | 1 | 1 | 1 | 1 | 1 | 1 |
| Head Group Size of Anionic Surfactant | Small | Small | Small | Small | Small | Small |
| Primary Chain Length of Anionic Surfactant | 12 | 12 | 12 | 12 | 12 | 12 |

* Acumer 1020 sold by Rohm & Haas

| <u>Component</u> | <u>Ex. 11</u> | <u>Ex. 12</u> | <u>Ex. 13</u> | <u>Ex. 14</u> | <u>Ex. 15</u> |
|----------------------------------------------------------------|---------------|---------------|---------------|---------------|---------------|
| Mineral oil | 1.00% | 1.00% | 1.00% | 1.00% | 1.00% |
| Propylene glycol | 1.00% | 1.00% | 1.00% | 1.00% | 1.00% |
| Ammonium Lauryl Sulfate | 0.00% | 0.00% | 0.00% | 0.00% | 0.60% |
| Ammonium Laureth Sulfate | 0.00% | 5.00% | 0.00% | 0.00% | 0.00% |
| Hostapur SAS 60 (SPS) | 1.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| C ₁₄ -C ₁₆ Sodium Alpha Olefin Sulfonate | 0.00% | 0.00% | 2.00% | 0.00% | 0.00% |
| Sodium Lauroyl Sarcosinate | 0.00% | 0.00% | 0.00% | 1.00% | 0.00% |
| Citric Acid | 0.055% | 7.50% | 0.00% | 0.00% | 0.00% |
| Sodium Citrate | 0.00% | 4.00% | 2.00% | 0.00% | 0.00% |
| Succinic Acid | 4.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Sodium Succinate | 0.67% | 0.00% | 0.00% | 0.00% | 0.00% |
| Malic Acid | 0.00% | 0.00% | 2.50% | 0.00% | 0.00% |
| Malonic Acid | 0.00% | 0.00% | 0.00% | 4.00% | 0.00% |
| Sodium Malonate | 0.00% | 0.00% | 0.00% | 3.20% | 0.00% |
| Salicylic Acid | 0.00% | 0.00% | 0.00% | 0.00% | 0.50% |
| Steareth 20 | 0.55% | 0.55% | 0.55% | 0.55% | 0.55% |
| Steareth 2 | 0.45% | 0.45% | 0.45% | 0.45% | 0.45% |
| Triclosan® | 0.15% | 3.00% | 0.15% | 0.01% | 0.15% |
| Cocamidopropyl Betaine | 0.00% | 0.00% | 0.00% | 4.00% | 0.00% |
| Polyquaternium 10 | 0.00% | 0.00% | 0.00% | 0.40% | 0.00% |
| Miscellaneous | 0.36% | 0.36% | 0.36% | 0.36% | 0.36% |
| Water | q.s. | q.s. | q.s. | q.s. | q.s. |
| pH | 3-6 | 3-6 | 3-6 | 3-6 | 3-6 |
| Microtox of Anionic Surfactant | n/a | 150 | 20 | <150 | 1 |

| | | | | | |
|--------------------------------------------|-------|-------|-------|-------|-------|
| Head Group Size of Anionic Surfactant | Small | Large | Small | Large | Small |
| Primary Chain Length of Anionic Surfactant | 15.5 | 12 | 14-16 | 12 | 12 |

The antimicrobial cleansing compositions shown all have a Gram Negative Residual Effectiveness Index of greater than 0.3, a Gram Positive Residual Effectiveness Index of greater than 1.0, a One-wash Immediate Germ Reduction Index of greater than 1.3; and a Mildness Index of greater than 0.3.

Procedure for Making Antimicrobial Cleansing Composition Examples

When mineral oil is used, premix mineral oil, propylene glycol, active, steareth 2 and 20, oleth 2 and 20, and 50%, by weight of the oil, glycol, active, steareth and oleth materials, water to a premix vessel. Heat to $165^{\circ}\text{F} \pm 10^{\circ}\text{F}$. Add additional 50%, by weight of the oil, glycol, active, steareth and oleth materials, of water to the premix tank.

Add all but 5 weight percent of remaining water to second mix tank. If required, add premix to the mix tank. Add surfactants to mix tank. Heat materials to $155^{\circ}\text{F} \pm 10^{\circ}\text{F}$ and mix until dissolved. Cool to less than 100°F , add acid and antibacterial active, if not in premix, and perfumes. Mix until materials are dissolved. Adjust pH to target with required buffer (NaOH or buffer salt). Add remaining water to complete product.

Procedure for Making Antimicrobial Wipe Examples

Compositions 1-15 are impregnated onto absorbent sheets as follows:

Composition 1-15 are impregnated onto a wet and air laid woven absorbent sheet comprised of 85% cellulose and 15% polyester at 260% by weight of the absorbent sheet by pouring the composition onto the sheet via a cup.

Composition 1-15 are impregnated onto a wet and air laid woven absorbent sheet comprised of 100% cellulose at 260% by weight of the sheet by pouring the composition onto the sheet via a cup.

Compositions 1-15 are impregnated onto separate wet and air laid nonwoven absorbent sheets comprised of 50% cellulose and 50% polyester at 260% by weight of the sheet by pouring the compositions onto the sheets via a cup.

WHAT IS CLAIMED IS:

1. An antimicrobial wipe characterized in that it comprises a porous or absorbent sheet impregnated with an antimicrobial cleansing composition, wherein the antimicrobial cleansing composition comprises:
 - a. from 0.001% to 5.0%, by weight of the antimicrobial cleansing composition, of an antimicrobial active;
 - b. from 0.05% to 10%, by weight of the antimicrobial cleansing composition, of an anionic surfactant;
 - c. from 0.1% to 10%, by weight of the antimicrobial cleansing composition, of a proton donating agent; and
 - d. from 3% to 99.85%, by weight of the antimicrobial cleansing composition, water;wherein the composition is adjusted to a pH of from 3.0 to 6.0;
wherein the antimicrobial cleansing composition has a Gram Negative Residual Effectiveness Index of greater than 0.3.
2. An antimicrobial wipe characterized in that it comprises a porous or absorbent sheet impregnated with an antimicrobial cleansing composition, wherein the antimicrobial cleansing composition comprises:
 - a. from 0.001% to 5.0%, by weight of the antimicrobial cleansing composition, of an antimicrobial active;
 - b. from 0.05% to 10%, by weight of the antimicrobial cleansing composition, of an anionic surfactant;
 - c. from 0.1% to 10%, by weight of the antimicrobial cleansing composition, of a proton donating agent; and
 - d. from 3% to 99.85%, by weight of the antimicrobial cleansing composition, water;wherein the composition is adjusted to a pH of from 3.0 to 6.0;
wherein the antimicrobial cleansing composition has a Gram Positive Residual Effectiveness Index of greater than 0.5.
3. An antimicrobial wipe characterized in that it is effective against Gram positive bacteria, Gram negative bacteria, fungi, yeasts, molds, and viruses comprising a porous or absorbent sheet impregnated with an antimicrobial cleansing composition, wherein the antimicrobial cleansing composition comprises:
 - a. from 0.001% to 5.0%, by weight of the antimicrobial cleansing composition, of an antimicrobial active;

- b. from 0.05% to 10%, by weight of the antimicrobial cleansing composition, of an anionic surfactant;
 - c. from 0.1% to 10%, by weight of the antimicrobial cleansing composition, of a proton donating agent; and
 - d. from 3% to 99.85%, by weight of the antimicrobial cleansing composition, water; wherein the composition is adjusted to a pH of from 3.0 to 6.0; wherein the antimicrobial cleansing composition has a One-wash Immediate Germ Reduction Index of greater than 1.3.
- 4. An antimicrobial wipe comprising according to any of the preceding claims which also has a Mildness Index of greater than 0.3.
 - 5. An antimicrobial wipe according to any of the preceding claims further comprising from 0.1% to 30%, by weight of the antimicrobial cleansing composition, of a lipophilic skin moisturizing agent.
 - 6. An antimicrobial wipe according to any of the preceding claims wherein the antimicrobial active is selected from the group consisting of Triclosan®, Triclocarban®, Octopirox®, PCMX, ZPT, natural essential oils and their key ingredients, and mixtures thereof.
 - 7. An antimicrobial wipe according to any of the preceding claims wherein the anionic surfactant has a Microtox Index of less than 150.
 - 8. An antimicrobial wipe according to any of the preceding claims wherein the anionic surfactant is selected from the group consisting of sodium and ammonium alkyl sulfates and ether sulfates having chain lengths of predominantly 12 and 14 carbon atoms, olefin sulfates having chain lengths of predominantly 14 and 16 carbon atoms, and paraffin sulfonates having an average chain length of from 13 to 17 carbon atoms, and mixtures thereof.
 - 9. An antimicrobial wipe according to any of the preceding claims wherein the proton donating agent is an organic acid having a Buffering Capacity of greater than 0.005.
 - 10. An antimicrobial wipe according to any of the preceding claims wherein the proton donating agent is selected from the group comprising adipic acid, tartaric acid, citric acid,

maleic acid, malic acid, succinic acid, glycolic acid, glutaric acid, benzoic acid, malonic acid, salicylic acid, gluconic acid, polyacrylic acid, their salts, and mixtures thereof.

11. An antimicrobial wipe according to any of claims 1 through 8 wherein the proton donating agent is a mineral acid.
12. An antimicrobial wipe according to any of the preceding claims wherein the ratio of the amount of non-anionic surfactants to the amount of anionic surfactant comprising the antibacterial cleansing composition is less than 1:1.
13. A method for providing improved residual effectiveness against Gram negative bacteria comprising the use of a safe and effective amount of the composition of any of the preceding claims on human skin.
14. A method for treating acne comprising the use of a safe and effective amount of the composition of any of the preceding claims on human skin.

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K7/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C11D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--------------------------------------------------------------------------------------------------|-----------------------|
| X | EP 0 613 675 A (JOHNSON & JOHNSON CONSUMER) 7 September 1994 see the whole document --- | 1 |
| P, X | WO 98 15262 A (PROCTER & GAMBLE) 16 April 1998 see the whole document --- | 1 |
| P, X | WO 98 18445 A (PROCTER & GAMBLE) 7 May 1998 see the whole document --- | 1 |
| A | GB 2 288 811 A (PROCTER & GAMBLE) 1 November 1995 see the whole document --- | 1-11 |
| | --- -/-- | |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

1 October 1998

Date of mailing of the international search report

07/10/1998

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Couckuyt, P

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| A | WO 95 32705 A (UNILEVER PLC ;UNILEVER NV (NL)) 7 December 1995 see the whole document see page 10, line 25 - page 13, line 16 --- | 1-11 |
| A | WO 97 07781 A (UNILEVER PLC ;UNILEVER NV (NL)) 6 March 1997 see the whole document --- | 1-11 |
| A | EP 0 619 074 A (KIMBERLY CLARK CO) 12 October 1994 see the whole document --- | 1 |
| A | WO 96 29983 A (COLGATE PALMOLIVE CO ;RAMACHANDRAN PALLASSANA N (US); ROBBINS CLAR) 3 October 1996 see claims --- | 1 |
| A | WO 96 17918 A (RABONE KENNETH LESLIE ;ALLAN ALEXANDER (GB); SHARPLES MARTIN (GB);) 13 June 1996 see the whole document --- | 1 |
| A | WO 95 03781 A (PROCTER & GAMBLE) 9 February 1995 see the whole document --- | 1 |
| A | WO 96 17592 A (PROCTER & GAMBLE) 13 June 1996 see the whole document --- | 1 |
| A | WO 92 18100 A (PROCTER & GAMBLE) 29 October 1992 see the whole document --- | 1 |
| A | WO 96 21426 A (PROCTER & GAMBLE) 18 July 1996 see the whole document --- | 1 |
| A | WO 97 03647 A (PROCTER & GAMBLE) 6 February 1997 see the whole document --- | 1 |
| A | WO 93 09761 A (RICHARDSON VICKS INC) 27 May 1993 see the whole document --- | 1 |
| A | WO 95 00116 A (PROCTER & GAMBLE) 5 January 1995 see the whole document ----- | 1 |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/10973

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-7
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/ US 98 /10973

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

The physical characteristics "Gram Negavite/Positive Residual Effectiveness Index", "One-wash Immediate Germ Reduction Index", "Milness Index" and "Microtox Index" are unusual parameters in the field of cosmetics. The search was limited to the general inventive idea of the description and claims.

| Patent document cited in search report | | Publication date | Patent family member(s) | | Publication date |
|-------------------------------------------|---|---------------------|----------------------------|---|---------------------|
| EP 0613675 | A | 07-09-1994 | AU 682333 | B | 02-10-1997 |
| | | | AU 5756194 | A | 08-09-1994 |
| | | | BR 9400829 | A | 01-11-1994 |
| | | | CA 2117136 | A | 06-09-1994 |
| | | | GR 1002595 | B | 12-02-1997 |
| | | | ZA 9401547 | A | 04-09-1995 |
| WO 9815262 | A | 16-04-1998 | NONE | | |
| WO 9818445 | A | 07-05-1998 | AU 4997697 | A | 22-05-1998 |
| GB 2288811 | A | 01-11-1995 | NONE | | |
| WO 9532705 | A | 07-12-1995 | US 5681802 | A | 28-10-1997 |
| | | | AU 2735595 | A | 21-12-1995 |
| | | | BR 9507819 | A | 16-09-1997 |
| | | | CA 2186011 | A | 07-12-1995 |
| | | | CN 1148803 | A | 30-04-1997 |
| | | | CZ 9603500 | A | 14-05-1997 |
| | | | EP 0762868 | A | 19-03-1997 |
| | | | HU 76537 | A | 29-09-1997 |
| | | | JP 10500962 | T | 27-01-1998 |
| | | | PL 317427 | A | 14-04-1997 |
| | | | SK 152596 | A | 04-06-1997 |
| WO 9707781 | A | 06-03-1997 | AU 6927496 | A | 19-03-1997 |
| | | | EP 0855905 | A | 05-08-1998 |
| | | | PL 325173 | A | 06-07-1998 |
| EP 0619074 | A | 12-10-1994 | AU 5913794 | A | 06-10-1994 |
| | | | CA 2098429 | A | 01-10-1994 |
| | | | JP 7000310 | A | 06-01-1995 |
| WO 9629983 | A | 03-10-1996 | AU 5318596 | A | 16-10-1996 |
| WO 9617918 | A | 13-06-1996 | AU 2673395 | A | 15-01-1996 |
| | | | AU 689354 | B | 26-03-1998 |
| | | | AU 4177296 | A | 26-06-1996 |
| | | | BR 9508088 | A | 12-08-1997 |
| | | | BR 9509886 | A | 21-10-1997 |

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|-------------------------------------------|---------------------|----------------------------|---------------------|
| WO 9617918 A | | CA 2206771 A | 13-06-1996 |
| | | CZ 9701744 A | 17-06-1998 |
| | | EP 0766729 A | 09-04-1997 |
| | | EP 0796315 A | 24-09-1997 |
| | | JP 10501832 T | 17-02-1998 |
| | | PL 317896 A | 28-04-1997 |
| | | PL 320639 A | 13-10-1997 |
| | | CA 2189018 A | 28-12-1995 |
| | | CN 1151180 A | 04-06-1997 |
| | | WO 9535364 A | 28-12-1995 |
| | | HU 77302 A | 30-03-1998 |
| | | SK 71197 A | 08-10-1997 |
| | | US 5631218 A | 20-05-1997 |
| | | | |
| WO 9503781 A | 09-02-1995 | CA 2168543 A | 09-02-1995 |
| | | CN 1130864 A | 11-09-1996 |
| | | EP 0714283 A | 05-06-1996 |
| | | JP 9501161 T | 04-02-1997 |
| WO 9617592 A | 13-06-1996 | BR 9509865 A | 30-09-1997 |
| | | CA 2207031 A | 13-06-1996 |
| | | CN 1169112 A | 31-12-1997 |
| | | EP 0796084 A | 24-09-1997 |
| | | US 5674511 A | 07-10-1997 |
| WO 9218100 A | 29-10-1992 | AU 1881792 A | 17-11-1992 |
| | | BR 9205895 A | 27-09-1994 |
| | | CA 2107001 A | 16-10-1992 |
| | | CN 1066779 A | 09-12-1992 |
| | | EP 0580814 A | 02-02-1994 |
| | | FI 934541 A | 14-10-1993 |
| | | JP 6506938 T | 04-08-1994 |
| | | MX 9201733 A | 01-10-1992 |
| | | NO 933675 A | 15-12-1993 |
| | | PT 100360 A | 30-06-1993 |
| WO 9621426 A | 18-07-1996 | CN 1176595 A | 18-03-1998 |
| | | EP 0802786 A | 29-10-1997 |
| WO 9703647 A | 06-02-1997 | US 5607980 A | 04-03-1997 |

PCT/US 98/10973

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|-------------------------------------------|---------------------|----------------------------|---------------------|
| WO 9703647 A | | AU 6676996 A | 18-02-1997 |
| | | CZ 9800170 A | 17-06-1998 |
| | | EP 0841898 A | 20-05-1998 |
| WO 9309761 A | 27-05-1993 | AU 3136593 A | 15-06-1993 |
| | | CA 2122272 A | 27-05-1993 |
| | | EP 0613369 A | 07-09-1994 |
| | | JP 7501077 T | 02-02-1995 |
| | | MX 9206741 A | 01-05-1993 |
| | | PT 101082 A | 28-02-1994 |
| | | US 5439682 A | 08-08-1995 |
| | | US 5599549 A | 04-02-1997 |
| | | US 5560918 A | 01-10-1996 |
| WO 9500116 A | 05-01-1995 | BR 9406807 A | 23-07-1996 |
| | | CA 2165050 A | 05-01-1995 |
| | | CN 1135174 A | 06-11-1996 |
| | | EP 0702550 A | 27-03-1996 |
| | | JP 8511962 T | 17-12-1996 |
| | | US 5650384 A | 22-07-1997 |
| | | US 5804539 A | 08-09-1998 |